Difference between revisions of "IRIS"

Latest revision as of 13:02, 11 March 2014

This page provides a description and a link to a "IRIS" database that provides information needed when modeling exposure levels or performing exposure assessment.

Short description

IRIS is a database of human health effects that may result from exposure to various substances found in the environment. The heart of the IRIS system is its collection of computer files covering individual chemicals. These chemical files contain descriptive and quantitative information in the following categories: a) Oral reference doses and inhalation reference concentrations (RfDs and RfCs, respectively) for chronic noncarcinogenic health effects, b) Hazard identification, oral slope factors, and oral and inhalation unit risks for carcinogenic effects. Database includes over 500 chemicals.

Long description

http://www.nlm.nih.gov/pubs/factsheets/irisfs.html

Link

http://www.epa.gov/iris/

Key words

human health effects, exposure, toxicology, carcinogenity, hazards

Data scrapping

IRIS database is accessible from this link: http://cfpub.epa.gov/ncea/iris/compare.cfm. The critical data can be obtained at once if all substances and all types of data are selected. A result is an html file with several tables from which the data can be scrapped and transformed into a better format. The January 4th, 2012, version was downloaded from IRIS and saved on this page (see the file below). Who could do this?

Reference system in IRIS database. The number (e.g. 0442) refers to the IRIS chemical identifier.

QuickView
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#reforal  Oral RfDs
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#refinhal Inhalation RfCs
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#woe      Weight-of-Evidence Characterizations
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#quaoral  Oral Slope Factors/Drinking Water Unit Risks
http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#quainhal Inhalation Unit Risks

IRIS Summary 
http://www.epa.gov/iris/subst/0442.htm#reforal
http://www.epa.gov/iris/subst/0442.htm#refinhal
http://www.epa.gov/iris/subst/0442.htm#woe
http://www.epa.gov/iris/subst/0442.htm#quaoral
http://www.epa.gov/iris/subst/0442.htm#quainhal

Toxicological Review (PDF)
http://www.epa.gov/iris/toxreviews/0128tr.pdf (this does not exist for many compounds)

←# : Tämähän alkaa olla oikein hyvä! Alla vielä muutamia kommentteja. --Jouni 20:34, 28 June 2012 (EEST)

Tulokset on tässä kirjoitettu muotoon 3.4x10-3. Joko interpret-funktiota on päivitettävä siten, että se ymmärtää tämän, tai sitten kaikki näiden taulukoiden tulokset pitää muuttaa muotoon 3.4e-3 (jonka R ymmärtää oikein, kun käytetään as.numericia). Tuntuu, että interpretin päivitys olisi parempi vaihtoehto.
Yksiköt pitäisi muuttaa tietokoneelle ymmärrettäväksi. Vaihtoehtoja: a) Unit conversions -sivulle lisätään kaikki tässä esiintyvät uudet yksiköt, niin että niille saadaan muunnosohjeet (esim. mg /kg-day → mg /kg /d tai per µg /m³ → m3 /µg. b) Kaikki yksiköt tällä sivulla muutetaan tuohon standardimuotoon. Mikä tuntuisi järkevältä?

⇤# : Jos jossakin taulukossa joka rivillä on sama yksikkö, koko saraketta ei tarvita vaan riittää yksikön ilmoittaminen osoiterivillä. --Jouni 20:34, 28 June 2012 (EEST)

⇤# : Ei tätä kannata tehdä rivi kerrallaan, vaan ottaa koko viiden taulukon tiedosto (ks. Related files) muokata siitä tekstinkäsittelyohjelmalla viisi t2b-taulukkoa. Etsi-korvaa-toiminnolla voi tehdä suurimman osan muotoiluista. Kannattaa kysyä apua jos ei osaa, koska muuten työssä menee päiviä. --Jouni 10:42, 20 June 2012 (EEST)

⇤#: Huomaa, että IRIS identifier on tärkeä. Se löytyy nettilinkeistä (esim. Acenaphthenen QuickView on tämmöinen linkki: http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#reforal ja siitä näkee, että tämän aineen IRIS identifier on 0442. --Jouni 10:42, 20 June 2012 (EEST)

References

Related files

Difference between revisions of "IRIS"

Latest revision as of 13:02, 11 March 2014

Contents

Short description

Long description

Link

Key words

Data scrapping

See also

References

Related files

Navigation menu

Personal tools

Namespaces

Variants

Views

More

Search

Navigation

Page Tools

Tools

In other websites

@@ Line 41: / Line 41: @@
   http://www.epa.gov/iris/toxreviews/0128tr.pdf (this does not exist for many compounds)
-===Oral RfDs===
+{{defend|# |Tämähän alkaa olla oikein hyvä! Alla vielä muutamia kommentteja.|--[[User:Jouni|Jouni]] 20:34, 28 June 2012 (EEST)}}
-Oral RfDs were scrapped as an example (chemical starting with A) on Jan 4, 2012.
+* Tulokset on tässä kirjoitettu muotoon 3.4x10-3. Joko interpret-funktiota on päivitettävä siten, että se ymmärtää tämän, tai sitten kaikki näiden taulukoiden tulokset pitää muuttaa muotoon 3.4e-3 (jonka R ymmärtää oikein, kun käytetään as.numericia). Tuntuu, että interpretin päivitys olisi parempi vaihtoehto.
+* Yksiköt pitäisi muuttaa tietokoneelle ymmärrettäväksi. Vaihtoehtoja: a) [[Unit conversions]] -sivulle lisätään kaikki tässä esiintyvät uudet yksiköt, niin että niille saadaan muunnosohjeet (esim. mg /kg-day &rarr; mg /kg /d tai per µg /m<sup>3</sup> &rarr; m3 /µg. b) Kaikki yksiköt tällä sivulla muutetaan tuohon standardimuotoon. Mikä tuntuisi järkevältä?
+{{attack|# |Jos jossakin taulukossa joka rivillä on sama yksikkö, koko saraketta ei tarvita vaan riittää yksikön ilmoittaminen osoiterivillä.|--[[User:Jouni|Jouni]] 20:34, 28 June 2012 (EEST)}}
 {{attack|# |Ei tätä kannata tehdä rivi kerrallaan, vaan ottaa koko viiden taulukon tiedosto (ks. Related files) muokata siitä tekstinkäsittelyohjelmalla viisi t2b-taulukkoa. Etsi-korvaa-toiminnolla voi tehdä suurimman osan muotoiluista. Kannattaa kysyä apua jos ei osaa, koska muuten työssä menee päiviä.|--[[User:Jouni|Jouni]] 10:42, 20 June 2012 (EEST)}}
@@ Line 52: / Line 56: @@
 |3 = --[[User:Jouni|Jouni]] 10:42, 20 June 2012 (EEST)}}
-<t2b index = "Substance,Observation type" locations = "CASRN,Critical Effact(s),Unit,Oral RfD,Type of RfD,Point of Departure(s)*,Overall Confidence,IRIS identifier" unit = "mg /kg-day">
+==See also==
-Acenaphthene|83-32-9| Hepatotoxicity|mg /kg-day|6 x10-2|NOAEL|175|Low|0442
-Acenaphthylene|208-96-8|Not Assessed under the IRIS program||||||0443
-Acephate|30560-19-1|Inhibition of brain ChE|mg /kg-day|4 x10-3|LEL|0.12|High|0354
-Acetaldehyde|75-07-0|Not Assessed under the IRIS program||||||0290
-Acetochlor|34256-82-1|Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males|mg /kg-day|2 x10-2|NOAEL|2 mg/kg-day|High|0521
-Acetone|67-64-1|Nephropathy|mg /kg-day|0.9|NOAEL|900|Medium|0128
-Acetonitrile|75-05-8|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0205
-Acetophenone|98-86-2|General toxicity|mg /kg-day|1 x10-1|NOAEL|423|Low|0321
-Acetyl chloride|75-36-5|Not Assessed under the IRIS program||||||0518
-Acifluorfen, sodium|62476-59-9|Mortality and kidney lesions|mg /kg-day|1.3 x10-2|NOEL|1.25|Medium|0192
-Acrolein|107-02-8|Decreased survival|mg /kg-day|5 x10-4|NOAEL|0.05|Medium/High|0364
-Acrylamide|79-06-1|Degenerative nerve changes|mg /kg-day|0.002|HED (BMDL)|0.053|Medium/High|0286
-Acrylic acid|79-10-7|Reduced pup weight|mg /kg-day|5 x10-1|NOAEL|53|High|0002
-Acrylonitrile|107-13-1|Not Assessed under the IRIS program||||||0206
-Adiponitrile|111-69-3|Not Assessed under the IRIS program||||||0515
-Alachlor|15972-60-8|Hemosiderosis, hemolytic anemia|mg /kg-day|1 x10-2|NOAEL|1|High|0129
-Alar|1596-84-5|No adverse effects|mg /kg-day|1.5 x10-1|NOEL|15|Low|0287
-Aldicarb|116-06-3|Sweating as clinical sign of AChe inhibition (other effect: Clinical signs and symptoms of acetylcholinesterase inhibition including sweating, pinpoint pupils, leg weakness, and other effects Nausea, diarrhea, and other signs and symptoms)|mg /kg-day|1 x10-3|NOAEL|0.01|Medium|0003
-Aldicarb sulfone|1646-88-4|Brain ChE inhibition in females|mg /kg-day|1 x10-3|NOAEL|0.11|Medium|0312
-Aldrin|309-00-2|Liver toxicity|mg /kg-day|3 x10-5|LOAEL|0.025|Medium|0130
-Ally|74223-64-6|Decreased body weight|mg /kg-day|2.5 x10-1|NOEL|25|High|0288
-Allyl alcohol|107-18-6|Impaired renal function and increased liver and kidney weights|mg /kg-day|5 x10-3|NOEL|4.8|Low|0004
-Allyl chloride|107-05-1|Not Assessed under the IRIS program||||||0387
-Aluminum phosphide|20859-73-8|Body weight and clinical parameters|mg /kg-day|4 x10-4|NOAEL|0.043|Medium|0005
-Amdro|67485-29-4|Increased organ weights|mg /kg-day|3 x10-4|NOEL|0.33|High|0207
-Ametryn|834-12-8|Liver toxicity|mg /kg-day|9 x10-3|NOEL|8.6|Low|0208
--Aminopyridine|504-24-5|Not Assessed under the IRIS program||||||0440
-Amitraz|33089-61-1|Increased mean blood sugar concentration; slight hypothermia|mg /kg-day|2.5 x10-3|NOEL|0.25|Medium|0334
-Ammonia|7664-41-7|Not Assessed under the IRIS program||||||0422
-Ammonium acetate|631-61-8|Not Assessed under the IRIS program||||||0517
-Ammonium methacrylate|16325-47-6|Not Assessed under the IRIS program||||||0516
-Ammonium sulfamate|7773-06-0|Decrease in body weight|mg /kg-day|2 x10-1|NOEL|214.3|Low|0007
-Aniline|62-53-3|Not Assessed under the IRIS program||||||0350
-ortho-Anisidine|90-04-0|Not Assessed under the IRIS program||||||0610
-Anthracene|120-12-7|No observed effects|mg /kg-day|3 x10-1|NOEL|1000|Low|0434
-Antimony|7440-36-0|Longevity, blood glucose, and cholesterol|mg /kg-day|4 x10-4|LOAEL|0.35|Low|0006
-Antimony trioxide|1309-64-4|Not Assessed under the IRIS program||||||0676
-Apollo|74115-24-5|Liver effects; organ weight changes|mg /kg-day|1.3 x10-2|NOEL|1.25|High|0008
-Aramite|140-57-8|Not Assessed under the IRIS program||||||0473
-Aroclor 1016|12674-11-2|Reduced birth weights|mg /kg-day|7 x10-5|NOAEL|0.007|Medium|0462
-Aroclor 1248|12672-29-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0649
-Aroclor 1254|11097-69-1|Ocular exudate, inflamed and prominent Meibomian glands, distorted growth of finger and toe nails; decreased antibody (IgG and IgM) response to sheep erythrocytes|mg /kg-day|2 x10-5|LOAEL|0.005|Medium|0389
-Arsenic, inorganic|7440-38-2|Hyperpigmentation, keratosis and possible vascular complications|mg /kg-day|3 x10-4|NOAEL|0.0008|Medium|0278
-Arsine|7784-42-1|Not Assessed under the IRIS program||||||0672
-Asbestos|1332-21-4|Not Assessed under the IRIS program||||||0371
-Assure|76578-14-8|Liver cell enlargement|mg /kg-day|9 x10-3|NOEL|0.9|High|0335
-Asulam|3337-71-1|Lower ovarian weight, lower liver/body weight|mg /kg-day|5 x10-2|LEL|50|Medium|0284
-Atrazine|1912-24-9|Decreased body weight gain (other effect: Cardiac toxicity and moderate-to-severe dilation of the right atrium)|mg /kg-day|3.5 x10-2|NOAEL|3.5|High|0209
-Avermectin B1|65195-55-3|Increased retinal folds in weanlings, decreased viability and lactation indices, decreased pup body weight, increase of dead pups at birth|mg /kg-day|4 x10-4|NOEL|0.12|High|0381
-Azobenzene|103-33-3|Not Assessed under the IRIS program||||||0351
-Barium and Compounds|7440-39-3|Nephropathy|mg /kg-day|0.2|BMDL05|63|Medium|0010
-Barium cyanide|542-62-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0009
-Baygon|114-26-1|Mild cholinergic symptoms and RBD ChE inhibition|mg /kg-day|4 x10-3|LEL|0.36|Medium|0210
-Bayleton|43121-43-3|Decreased body weight gain, erythrocyte count and hemoglobin level|mg /kg-day|3 x10-2|NOEL|2.5|High|0131
-Baythroid|68359-37-5|Decreased body weights in males, inflammatory foci in kidneys of females|mg /kg-day|2.5 x10-2|NOEL|2.5|High|0132
-Benefin|1861-40-1|Depressed erythrocyte counts|mg /kg-day|3 x10-1|NOAEL|25|Medium|0133
-Benomyl|17804-35-2|Decreased pup weanling weights|mg /kg-day|5 x10-2|NOEL|5 mg/kg-day|High|0011
-Bentazon (Basagran)|25057-89-0|Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs (other effect: Dose-related increase in red areas (presumed blood) in feces; coagulation defect)|mg /kg-day|3.0 x10-2|NOAEL (ADJ)|3.2|Medium|0134
-Benz[a]anthracene|56-55-3|Not Assessed under the IRIS program||||||0454
-Benzaldehyde|100-52-7|Forestomach lesions, kidney toxicity|mg /kg-day|1 x10-1|NOEL|143|Low|0332
-Benzene|71-43-2|Decreased lymphocyte count|mg /kg-day|4.0 x10-3|BMDL|1.2|Medium|0276
-Benzidine|92-87-5|Brain cell vacuolization; liver cell alterations in females|mg /kg-day|3 x10-3|LOAEL|2.7|Medium|0135
-</t2b>
-===Inhalation RfCs===
-<t2b index = "Substance,Observation type" locations = "CASRN,Critical Effact(s),Unit,Inhalation RfC,Type of RfC,Point of Departure(s)*,Overall Confidence,IRIS identifier" unit = "mg /m<sup>3</sup>">
-Acenaphthene|83-32-9|Not Assessed under the IRIS program.||||||
-Acenaphthylene|208-96-8|Not Assessed under the IRIS program.||||||
-Acephate|30560-19-1|Not Assessed under the IRIS program.||||||
-Acetaldehyde|75-07-0|Degeneration of olfactory epithelium|mg /m<sup>3</sup>|9x10<sup>-3</sup>|NOAEL (HEC)|8.7|Low|0290
-Acetochlor|34256-82-1|Not Assessed under the IRIS program.||||||
-Acetone|67-64-1|Not Assessed under the IRIS program.||||||
-Acetonitrile|75-05-8|Not Assessed under the IRIS program.||||||
-Acetophenone|98-86-2|Mortality|mg /m<sup>3</sup>|6x10<sup>-2</sup>|NOAEL (HEC)|60|Medium|0205
-Acetyl chloride|75-36-5|Not Assessed under the IRIS program.||||||
-Acifluorfen, sodium|62476-59-9|Not Assessed under the IRIS program.||||||
-Acrolein|107-02-8|Nasal lesions|mg /m<sup>3</sup>|2x10<sup>-5</sup>|LOAEL (HEC)|0.02|Medium|0364
-Acrylamide|79-06-1|Degenerative nerve changes|mg /m<sup>3</sup>|0.006|HEC (BMDL)|0.18|Medium|0286
-Acrylic acid|79-10-7|Degeneration of the nasal olfactory epithelium|mg /m<sup>3</sup>|1x10<sup>-3</sup>|LOAEL (HEC)|0.33|Medium|0002
-Acrylonitrile|107-13-1|Degeneration and inflammation of nasal respiratory epithelium; hyperplasia of mucous secreting cells|mg /m<sup>3</sup>|2x10<sup>-3</sup>|LOAEL (HEC)|1.9|Medium|0206
-Adiponitrile|111-69-3|Not Assessed under the IRIS program.||||||
-Alachlor|15972-60-8|Not Assessed under the IRIS program.||||||
-Alar|1596-84-5|Not Assessed under the IRIS program.||||||
-Aldicarb|116-06-3|Not Assessed under the IRIS program.||||||
-Aldicarb sulfone|1646-88-4|Not Assessed under the IRIS program.||||||
-Aldrin|309-00-2|Not Assessed under the IRIS program.||||||
-Ally|74223-64-6|Not Assessed under the IRIS program.||||||
-Allyl alcohol|107-18-6|Not Assessed under the IRIS program.||||||
-Allyl chloride|107-05-1|Functional and histological peripheral neurotoxicity|mg /m<sup>3</sup>|1x10<sup>-3</sup>|NOAEL (HEC)|3.6|Low|0387
-Aluminum phosphide|20859-73-8|Not Assessed under the IRIS program.||||||
-Amdro|67485-29-4|Not Assessed under the IRIS program.||||||
-Ametryn|834-12-8|Not Assessed under the IRIS program.||||||
--Aminopyridine|504-24-5|Not Assessed under the IRIS program.||||||
-Amitraz|33089-61-1|Not Assessed under the IRIS program.||||||
-Ammonia|7664-41-7|Not Assessed under the IRIS program.||||||
-Ammonium acetate|631-61-8|Not Assessed under the IRIS program.||||||
-Ammonium methacrylate|16325-47-6|Not Assessed under the IRIS program.||||||
-Ammonium sulfamate|7773-06-0|Not Assessed under the IRIS program.||||||
-Aniline|62-53-3|Lack of toxicity (other effect: Mild spleen toxicity )|mg /m<sup>3</sup>|1x10<sup>-3</sup>|NOAEL (HEC)|3.4|Low|0350
-ortho-Anisidine|90-04-0|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0610
-Anthracene|120-12-7|Not Assessed under the IRIS program.||||||
-Antimony|7440-36-0|Not Assessed under the IRIS program.||||||
-Antimony trioxide|1309-64-4|Pulmonary toxicity, chronic interstitial inflammation|mg /m<sup>3</sup>|2x10<sup>-4</sup>|BMC<sub>10</sub> (HEC)|0.074|Medium|0676
-Apollo|74115-24-5|Not Assessed under the IRIS program.||||||
-Aramite|140-57-8|Not Assessed under the IRIS program.||||||
-Aroclor 1016|12674-11-2|Not Assessed under the IRIS program.||||||
-Aroclor 1248|12672-29-6|Not Assessed under the IRIS program.||||||
-Aroclor 1254|11097-69-1|Not Assessed under the IRIS program.||||||
-Arsenic, inorganic|7440-38-2|Not Assessed under the IRIS program.||||||
-Arsine|7784-42-1|Increased hemolysis, abnormal RBC morphology, and increased spleen weight (other effect: Increased hemolysis, increased spleen weight, and impaired compensatory erythropoiesis)|mg /m<sup>3</sup>|5x10<sup>-5</sup>|NOAEL (HEC)|0.014|Medium|0672
-Asbestos|1332-21-4|Not Assessed under the IRIS program.||||||
-Assure|76578-14-8|Not Assessed under the IRIS program.||||||
-Asulam||Not Assessed under the IRIS program.||||||
-Atrazine||Not Assessed under the IRIS program.||||||
-Avermectin B1||Not Assessed under the IRIS program.||||||
-Azobenzene||Not Assessed under the IRIS program.||||||
-Barium and Compounds||Not Assessed under the IRIS program.||||||
-Barium cyanide||Not Assessed under the IRIS program.||||||
-Baygon||Not Assessed under the IRIS program.||||||
-Bayleton||Not Assessed under the IRIS program.||||||
-Baythroid||Not Assessed under the IRIS program.||||||
-Benefin||Not Assessed under the IRIS program.||||||
-Benomyl||Not Assessed under the IRIS program.||||||
-Bentazon (Basagran)||Not Assessed under the IRIS program.||||||
-Benz[a]anthracene||Not Assessed under the IRIS program.||||||
-Benzaldehyde||Not Assessed under the IRIS program.||||||
-Benzene|71-43-2|Decreased lymphocyte count|mg /m<sup>3</sup>|3x10<sup>-2</sup>|BMCL|8.2|Medium|0276
-Benzidine|92-87-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0135
-Benzo[a]pyrene (BaP)||Not Assessed under the IRIS program.||||||
-Benzo[b]fluoranthene||Not Assessed under the IRIS program.||||||
-Benzo[g,h,i]perylene||Not Assessed under the IRIS program.||||||
-Benzo[k]fluoranthene||Not Assessed under the IRIS program.||||||
-Benzoic acid||Not Assessed under the IRIS program.||||||
-Benzotrichloride||Not Assessed under the IRIS program.||||||
-Benzyl chloride|100-44-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0393
-Beryllium and compounds|7440-41-7|Beryllium sensitization and progression to CBD|mg /m<sup>3</sup>|2x10<sup>-5</sup>|LOAEL (HEC)|0.0002|Medium|0012
-Bidrin||Not Assessed under the IRIS program.||||||
-Biphenthrin||Not Assessed under the IRIS program.||||||
-,1-Biphenyl|92-52-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0013
-Bis(2-chloro-1-methylethyl) ether||Not Assessed under the IRIS program.||||||
-Bis(2-chloroethoxy)methane||Not Assessed under the IRIS program.||||||
-Bis(chloroethyl)ether (BCEE)|111-44-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0137
-Bis(chloromethyl)ether (BCME)|542-88-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0375
-Bisphenol A.|80-05-7|Not Assessed under the IRIS program.||||||
-Boron and Compounds||Information reviewed but value not estimated. Refer to IRIS Summary.||||||0410
-Bromate|15541-45-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||1002
-Brominated dibenzofurans|NA|Not Assessed under the IRIS program.||||||
-Bromobenzene|108-86-1|Hepatocellular cytomegaly in female B6C3F1 mice|mg /m<sup>3</sup>|6x10<sup>-2</sup>|BMCL<sub>10</sub> (HEC)|63|Low/Medium|1020
-Bromochloromethane||Not Assessed under the IRIS program.||||||
-Bromodichloromethane||Not Assessed under the IRIS program.||||||
-p-Bromodiphenyl ether||Not Assessed under the IRIS program.||||||
-Bromoform|75-25-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0214
-Bromomethane|74-83-9|Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity|mg /m<sup>3</sup>|5x10<sup>-3</sup>|LOAEL (HEC)|0.48|High|0015
-Bromotrichloromethane||Not Assessed under the IRIS program.||||||
-Bromoxynil||Not Assessed under the IRIS program.||||||
-Bromoxynil octanoate||Not Assessed under the IRIS program.||||||
-,3-Butadiene|106-99-0|Ovarian atrophy|mg /m<sup>3</sup>|2x10<sup>-3</sup>|BMCL<sub>10</sub> (HEC)|1.98|Medium|0139
-n-Butanol||Not Assessed under the IRIS program.||||||
-Butyl benzyl phthalate||Not Assessed under the IRIS program.||||||
-Butylate||Not Assessed under the IRIS program.||||||
-t-Butylchloride||Not Assessed under the IRIS program.||||||
-Butylphthalyl butylglycolate (BPBG)||Not Assessed under the IRIS program.||||||
-Cacodylic acid||Not Assessed under the IRIS program.||||||
-Cadmium||Not Assessed under the IRIS program.||||||
-Calcium cyanide||Not Assessed under the IRIS program.||||||
-Caprolactam|105-60-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0357
-Captafol||Not Assessed under the IRIS program.||||||
-Captan||Not Assessed under the IRIS program.||||||
-Carbaryl|63-25-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0019
-Carbofuran||Not Assessed under the IRIS program.||||||
-Carbon disulfide|75-15-0|Peripheral nervous system dysfunction|mg /m<sup>3</sup>|7x10<sup>-1</sup>|BMC<sub>10</sub> (HEC)|19.7|Medium|0217
-Carbon tetrachloride|56-23-5|Not Assessed under the IRIS program.|Fatty changes in the liver|mg /m<sup>3</sup>|0.1|BMCL<sub>10</sub> (HEC)|14.3|0020
-Carbonyl sulfide|463-58-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0617
-Carbosulfan||Not Assessed under the IRIS program.||||||
-Carboxin||Not Assessed under the IRIS program.||||||
-Cerium Oxide and Cerium Compounds|1306-38-3|Increased incidence of alveolar epithelial hyperplasia in the lungs of male and female rats|mg /m<sup>3</sup>|9x10<sup>-4</sup>|BMCL (HEC)|0.86|Low|1018
-Chloral hydrate||Not Assessed under the IRIS program.||||||
-Chloramben||Not Assessed under the IRIS program.||||||
-Chlordane (Technical)|12789-03-6|Hepatic effects|mg /m<sup>3</sup>|7x10<sup>-4</sup>|NOAEL (HEC)|0.65|Low|0142
-Chlordecone (Kepone)|143-50-0|Information reviewed but value not estimated. Refer to IRIS Summary.||||||1017
-Chlorimuron-ethyl||Not Assessed under the IRIS program.||||||
-Chlorine||Not Assessed under the IRIS program.||||||
-Chlorine cyanide||Not Assessed under the IRIS program.||||||
-Chlorine dioxide|10049-04-4|Vascular congestion and peribronchial edema (other effect: Hemorrhagic alveoli and congested capillaries in the lungs)|mg /m<sup>3</sup>|2x10<sup>-4</sup>|LOAEL (HEC)|0.64|Low|0496
-Chlorite (sodium salt)|7758-19-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0648
--Chloro-1,1-difluoroethane|75-68-3|No adverse effects|mg /m<sup>3</sup>|5x10<sup>1</sup>|NOAEL (HEC)|14710|Medium|0661
--Chloroacetophenone|532-27-4|Squamous hyperplasia of the nasal respiratory epithelium|mg /m<sup>3</sup>|3x10<sup>-5</sup>|LOAEL (HEC)|0.03|Low|0537
-p-Chloroaniline||Not Assessed under the IRIS program.||||||
-Chlorobenzene||Not Assessed under the IRIS program.||||||
-Chlorobenzilate||Not Assessed under the IRIS program.||||||
--Chlorobutane||Not Assessed under the IRIS program.||||||
--Chlorobutane||Not Assessed under the IRIS program.||||||
-Chlorocyclopentadiene||Not Assessed under the IRIS program.||||||
-Chlorodifluoromethane|75-45-6|Increased kidney, adrenal and pituitary weights (other effect: Reduced maternal weight gain)|mg /m<sup>3</sup>|5x10<sup>1</sup>|NOAEL (HEC)|5260|Medium|0657
-Chloroform||Not Assessed under the IRIS program.||||||
-Chloromethyl methyl ether (CMME)||Not Assessed under the IRIS program.||||||
-beta-Chloronaphthalene||Not Assessed under the IRIS program.||||||
--Chlorophenol||Not Assessed under the IRIS program.||||||
-p-Chlorophenyl methyl sulfide||Not Assessed under the IRIS program.||||||
-p-Chlorophenyl methyl sulfone||Not Assessed under the IRIS program.||||||
-p-Chlorophenyl methyl sulfoxide||Not Assessed under the IRIS program.||||||
-Chloroprene|126-99-8|Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively|mg /m<sup>3</sup>|2x10<sup>-2</sup>|BMDL (HEC)|2|Medium/High|1021
-Chlorothalonil||Not Assessed under the IRIS program.||||||
-o-Chlorotoluene||Not Assessed under the IRIS program.||||||
-Chlorpropham||Not Assessed under the IRIS program.||||||
-Chlorpyrifos||Not Assessed under the IRIS program.||||||
-Chlorsulfuron||Not Assessed under the IRIS program.||||||
-Chromium(III), insoluble salts|16065-83-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0028
-Chromium(VI) (Chromic acid mists and dissolved Cr(VI) aerosols)|18540-29-9|Nasal septum atrophy|mg /m<sup>3</sup>|8x10<sup>-6</sup>|LOAEL (ADJ)|0.000714|Low|0144
-Chromium(VI) (Cr(VI) particulates)|18540-29-9|Lactate dehydrogenase in bronchioalveolar lavage fluid||1x10<sup>-4</sup>|BMC<sub>10</sub> (ADJ)|0.034|Medium|0144
-Chrysene||Not Assessed under the IRIS program.||||||
-Coke oven emissions||Not Assessed under the IRIS program.||||||
-Copper||Not Assessed under the IRIS program.||||||
-Copper cyanide||Not Assessed under the IRIS program.||||||
-Creosote||Not Assessed under the IRIS program.||||||
-Crotonaldehyde||Not Assessed under the IRIS program.||||||
-Cumene|98-82-8|Increased kidney weights in female rats and adrenal weights in male and female rats|mg /m<sup>3</sup>|4x10<sup>-1</sup>|NOAEL (HEC)|435|Medium|0306
-Cyanazine||Not Assessed under the IRIS program.||||||
-Cyanide, free||Not Assessed under the IRIS program.||||||
-Cyanogen||Not Assessed under the IRIS program.||||||
-Cyanogen bromide||Not Assessed under the IRIS program.||||||
-Cyclohexane|110-82-7|Reduced pup weights in the F1 and F2 generations|mg /m<sup>3</sup>|6|BMCL<sub>1sd</sub> (HEC)|1822|Low/Medium|1005
-Cyclohexanone||Not Assessed under the IRIS program.||||||
-Cyclohexylamine||Not Assessed under the IRIS program.||||||
-Cyhalothrin/Karate||Not Assessed under the IRIS program.||||||
-Cypermethrin||Not Assessed under the IRIS program.||||||
-Cyromazine||Not Assessed under the IRIS program.||||||
-Dacthal||Not Assessed under the IRIS program.||||||
-Dalapon, sodium salt||Not Assessed under the IRIS program.||||||
-Danitol||Not Assessed under the IRIS program.||||||
-,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209)|1163-19-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0035
-Demeton||Not Assessed under the IRIS program.||||||
-Di (2-ethylhexyl)phthalate (DEHP)||Not Assessed under the IRIS program.||||||
-Di(2-ethylhexyl)adipate||Not Assessed under the IRIS program.||||||
-,4-Diaminotoluene|95-80-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0536
-Diazomethane|334-88-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0616
-Dibenz[a,h]anthracene||Not Assessed under the IRIS program.||||||
-Dibenzofuran||Not Assessed under the IRIS program.||||||
-,2-Dibromo-3-chloropropane (DBCP)|96-12-8|Testicular effects|mg /m<sup>3</sup>|2x10<sup>-4</sup>|NOAEL (HEC)|0.17|Medium|0414
-,4-Dibromobenzene||Not Assessed under the IRIS program.||||||
-Dibromochloromethane||Not Assessed under the IRIS program.||||||
-Dibromodichloromethane||Not Assessed under the IRIS program.||||||
-p,p'-Dibromodiphenyl ether||Not Assessed under the IRIS program.||||||
-,2-Dibromoethane|106-93-4|Nasal inflammation|mg /m<sup>3</sup>|9x10<sup>-3</sup>|BMCL<sub>10</sub> (HEC)|2.8|Medium|0361
-Dibutyl phthalate|84-74-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0038
-Dicamba||Not Assessed under the IRIS program.||||||
-Dichloroacetic acid|79-43-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0654
-,3-Dichlorobenzene||Not Assessed under the IRIS program.||||||
-,4-Dichlorobenzene|106-46-7|Increased liver weights in P1 males|mg /m<sup>3</sup>|8x10<sup>-1</sup>|NOAEL (HEC)|75|Medium|0552
-,2-Dichlorobenzene||Not Assessed under the IRIS program.||||||
-,3'-Dichlorobenzidine|91-94-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0504
-Dichlorodifluoromethane||Not Assessed under the IRIS program.||||||
-p,p'-Dichlorodiphenyl dichloroethane (DDD)||Not Assessed under the IRIS program.||||||
-p,p'-Dichlorodiphenyldichloroethylene (DDE)||Not Assessed under the IRIS program.||||||
-p,p'-Dichlorodiphenyltrichloroethane (DDT)||Not Assessed under the IRIS program.||||||
-,2-Dichloroethane||Not Assessed under the IRIS program.||||||
-,1-Dichloroethane||Not Assessed under the IRIS program.||||||
-trans-1,2-Dichloroethylene|156-60-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0314
-cis-1,2-Dichloroethylene|156-59-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0418
-,1-Dichloroethylene (1,1-DCE)|75-35-4|Liver toxicity (fatty change)|mg /m<sup>3</sup>|2x10<sup>-1</sup>|BMCL<sub>10</sub> (HEC)|6.9|Medium|0039
-Dichloromethane|75-09-2|Hepatic effects (hepatic vacuolation)|mg /m<sup>3</sup>|6x10<sup>-1</sup>|BMDL<sub>10</sub> (HEC)|17.2|Medium/High|0070
-,4-Dichlorophenol||Not Assessed under the IRIS program.||||||
--(2,4-Dichlorophenoxy)butyric acid (2,4-DB)||Not Assessed under the IRIS program.||||||
-,4-Dichlorophenoxyacetic acid (2,4-D)||Not Assessed under the IRIS program.||||||
-,2-Dichloropropane|78-87-5|Hyperplasia of the nasal mucosa|mg /m<sup>3</sup>|4x10<sup>-3</sup>|LOAEL (HEC)|1.3|Medium|0601
-,3-Dichloropropanol||Not Assessed under the IRIS program.||||||
-,3-Dichloropropene|542-75-6|Hypertrophy/ hyperplasia of the nasal respiratory epithelium|mg /m<sup>3</sup>|2x10<sup>-2</sup>|BMCL<sub>10</sub> (HEC)|0.72|High|0224
-Dichlorvos|62-73-7|Decreased brain cholinesterase activity|mg /m<sup>3</sup>|5x10<sup>-4</sup>|NOAEL (HEC)|0.05|Medium|0151
-Dicofol||Not Assessed under the IRIS program.||||||
-Dieldrin||Not Assessed under the IRIS program.||||||
-Diesel engine exhaust|NA|Pulmonary inflammation and histopathology|mg /m<sup>3</sup>|5x10<sup>-3</sup>|NOAEL (HEC)|0.144|Medium|0642
-Diethyl phthalate||Not Assessed under the IRIS program.||||||
-Diethyl sulfate|64-67-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0615
-Diethyl-p-nitrophenylphosphate||Not Assessed under the IRIS program.||||||
-Diethylene glycol dinitrate (DEGDN)||Not Assessed under the IRIS program.||||||
-Difenzoquat||Not Assessed under the IRIS program.||||||
-Diflubenzuron||Not Assessed under the IRIS program.||||||
-,1-Difluoroethane|75-37-6|No adverse effects observed|mg /m<sup>3</sup>|4x10<sup>1</sup>|NOAEL (HEC)|12051|Medium|0665
-Diisopropyl methylphosphonate (DIMP)||Not Assessed under the IRIS program.||||||
-Dimethipin||Not Assessed under the IRIS program.||||||
-Dimethoate||Not Assessed under the IRIS program.||||||
-Dimethyl phthalate|131-11-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0353
-Dimethyl sulfate|77-78-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0365
-Dimethyl terephthalate (DMT)||Not Assessed under the IRIS program.||||||
-Dimethylamine|124-40-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0228
-N-N-Dimethylaniline||Not Assessed under the IRIS program.||||||
-,3-Dimethylbenzidine|119-93-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0538
-N,N-Dimethylformamide|68-12-2|Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities|mg /m<sup>3</sup>|3x10<sup>-2</sup>|LOAEL (HEC)|7.9|Medium|0511
-,4-Dimethylphenol||Not Assessed under the IRIS program.||||||
-,6-Dimethylphenol||Not Assessed under the IRIS program.||||||
-,4-Dimethylphenol||Not Assessed under the IRIS program.||||||
-,6-Dinitro-o-cyclohexyl phenol||Not Assessed under the IRIS program.||||||
-m-Dinitrobenzene||Not Assessed under the IRIS program.||||||
-o-Dinitrobenzene||Not Assessed under the IRIS program.||||||
-,4-Dinitrophenol|51-28-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0152
-,4-Dinitrotoluene|121-14-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0542
-,4-/2,6-Dinitrotoluene mixture||Not Assessed under the IRIS program.||||||
-Dinoseb||Not Assessed under the IRIS program.||||||
-,4-Dioxane|123-91-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0326
-Diphenamid||Not Assessed under the IRIS program.||||||
-Diphenylamine||Not Assessed under the IRIS program.||||||
-,2-Diphenylhydrazine|122-66-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0049
-Diquat||Not Assessed under the IRIS program.||||||
-Disulfoton||Not Assessed under the IRIS program.||||||
-,4-Dithiane||Not Assessed under the IRIS program.||||||
-Diuron||Not Assessed under the IRIS program.||||||
-Dodine||Not Assessed under the IRIS program.||||||
-Endosulfan||Not Assessed under the IRIS program.||||||
-Endothall||Not Assessed under the IRIS program.||||||
-Endrin||Not Assessed under the IRIS program.||||||
-Epichlorohydrin|106-89-8|Changes in the nasal turbinates|mg /m<sup>3</sup>|1x10<sup>-3</sup>|NOAEL (HEC)|0.36|Medium|0050
-,2-Epoxybutane (EBU)|106-88-7|Degenerative lesions of the nasal cavity|mg /m<sup>3</sup>|2x10<sup>-2</sup>|LOAEL (HEC)|4.8|Medium|0630
-Ethephon||Not Assessed under the IRIS program.||||||
-Ethion||Not Assessed under the IRIS program.||||||
--Ethoxyethanol|110-80-5|Decreased testis weight, seminiferous tubule degeneration and decreased hemoglobin|mg /m<sup>3</sup>|2x10<sup>-1</sup>|NOAEL (HEC)|68|Medium|0513
-Ethyl acetate||Not Assessed under the IRIS program.||||||
-Ethyl carbamate|51-79-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0629
-Ethyl chloride|75-00-3|Delayed fetal ossification|mg /m<sup>3</sup>|1x10<sup>1<7sup>|NOAEL (HEC)|4000|Medium|0523
-S-Ethyl dipropylthiocarbamate (EPTC)||Not Assessed under the IRIS program.||||||
-Ethyl ether||Not Assessed under the IRIS program.||||||
-Ethyl p-nitrophenyl phenylphosphorothioate (EPN)||Not Assessed under the IRIS program.||||||
-Ethylbenzene|100-41-4|Developmental toxicity|mg /m<sup>3</sup>|1|NOAEL (HEC)|434|Low|0051
-Ethylene diamine|107-15-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0528
-Ethylene glycol||Not Assessed under the IRIS program.||||||
-Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol)|111-76-2|Hemosiderin deposition in the liver|mg /m<sup>3</sup>|1.6|BMCL (HEC)|16|Medium/High|0500
-Ethylene thiourea (ETU)||Not Assessed under the IRIS program.||||||
-Ethyleneimine|151-56-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0631
-Ethylphthalyl ethylglycolate (EPEG)||Not Assessed under the IRIS program.||||||
-Express||Not Assessed under the IRIS program.||||||
-Fenamiphos||Not Assessed under the IRIS program.||||||
-Fluometuron||Not Assessed under the IRIS program.||||||
-Fluoranthene||Not Assessed under the IRIS program.||||||
-Fluorene||Not Assessed under the IRIS program.||||||
-Fluorine (soluble fluoride)||Not Assessed under the IRIS program.||||||
-Fluridone||Not Assessed under the IRIS program.||||||
-Flurprimidol||Not Assessed under the IRIS program.||||||
-Flutolanil||Not Assessed under the IRIS program.||||||
-Fluvalinate||Not Assessed under the IRIS program.||||||
-Folpet||Not Assessed under the IRIS program.||||||
-Fomesafen||Not Assessed under the IRIS program.||||||
-Fonofos||Not Assessed under the IRIS program.||||||
-Formaldehyde||Not Assessed under the IRIS program.||||||
-Formic acid||Not Assessed under the IRIS program.||||||
-Fosetyl-al||Not Assessed under the IRIS program.||||||
-Furan||Not Assessed under the IRIS program.||||||
-Furfural||Not Assessed under the IRIS program.||||||
-Furmecyclox||Not Assessed under the IRIS program.||||||
-Glufosinate-ammonium||Not Assessed under the IRIS program.||||||
-Glycidaldehyde||Not Assessed under the IRIS program.||||||
-Glyphosate||Not Assessed under the IRIS program.||||||
-Haloxyfop-methyl||Not Assessed under the IRIS program.||||||
-Harmony||Not Assessed under the IRIS program.||||||
-Heptachlor||Not Assessed under the IRIS program.||||||
-Heptachlor epoxide||Not Assessed under the IRIS program.||||||
-n-Heptane||Not Assessed under the IRIS program.||||||
-Hexabromobenzene||Not Assessed under the IRIS program.||||||
-Hexabromodiphenyl ether||Not Assessed under the IRIS program.||||||
-,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153)|68631-49-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||1009
-Hexachlorobenzene|118-74-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0374
-Hexachlorobutadiene||Not Assessed under the IRIS program.||||||
-alpha-Hexachlorocyclohexane (alpha-HCH)||Not Assessed under the IRIS program.||||||
-beta-Hexachlorocyclohexane (beta-HCH)||Not Assessed under the IRIS program.||||||
-delta-Hexachlorocyclohexane (delta-HCH)||Not Assessed under the IRIS program.||||||
-epsilon-Hexachlorocyclohexane (epsilon-HC)||Not Assessed under the IRIS program.||||||
-gamma-Hexachlorocyclohexane (gamma-HCH)||Not Assessed under the IRIS program.||||||
-technical Hexachlorocyclohexane (t-HCH)||Not Assessed under the IRIS program.||||||
-Hexachlorocyclopentadiene (HCCPD)|77-47-4|Suppurative inflammation of the nose|mg /m<sup>3</sup>|2x10<sup>-4</sup>|NOAEL (HEC)|0.024|Medium|0059
-Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD||Not Assessed under the IRIS program.||||||
-Hexachloroethane|67-72-1|Neurotoxicity (tremors and ruffled pelt)|mg /m<sup>3</sup>|3x10<sup>-2</sup>|NOAEL (HEC)|83|Low|0167
-Hexachlorophene||Not Assessed under the IRIS program.||||||
-Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)||Not Assessed under the IRIS program.||||||
-,6-Hexamethylene diisocyanate||Not Assessed under the IRIS program.||||||
-n-Hexane||Not Assessed under the IRIS program.||||||
--Hexanone||Not Assessed under the IRIS program.||||||
-Hexazinone||Not Assessed under the IRIS program.||||||
-Hydrazine/Hydrazine sulfate||Not Assessed under the IRIS program.||||||
-Hydrogen Cyanide and Cyanide Salts||Not Assessed under the IRIS program.||||||
-Hydrogen chloride||Not Assessed under the IRIS program.||||||
-Hydrogen sulfide||Not Assessed under the IRIS program.||||||
-Hydroquinone||Not Assessed under the IRIS program.||||||
-Imazalil||Not Assessed under the IRIS program.||||||
-Imazaquin||Not Assessed under the IRIS program.||||||
-Indeno[1,2,3-cd]pyrene||Not Assessed under the IRIS program.||||||
-Iprodione||Not Assessed under the IRIS program.||||||
-Isobutyl alcohol||Not Assessed under the IRIS program.||||||
-Isophorone||Not Assessed under the IRIS program.||||||
-Isopropalin||Not Assessed under the IRIS program.||||||
-Isopropyl methyl phosphonic acid (IMPA)||Not Assessed under the IRIS program.||||||
-Isoxaben||Not Assessed under the IRIS program.||||||
-Lactofen||Not Assessed under the IRIS program.||||||
-Lead and compounds (inorganic)||Not Assessed under the IRIS program.||||||
-d-Limonene||Not Assessed under the IRIS program.||||||
-Linuron||Not Assessed under the IRIS program.||||||
-Londax||Not Assessed under the IRIS program.||||||
-Malathion||Not Assessed under the IRIS program.||||||
-Maleic anhydride||Not Assessed under the IRIS program.||||||
-Maleic hydrazide||Not Assessed under the IRIS program.||||||
-Maneb||Not Assessed under the IRIS program.||||||
-Manganese||Not Assessed under the IRIS program.||||||
-Mepiquat chloride||Not Assessed under the IRIS program.||||||
-Mercuric chloride (HgCl2)||Not Assessed under the IRIS program.||||||
-Mercury, elemental||Not Assessed under the IRIS program.||||||
-Merphos||Not Assessed under the IRIS program.||||||
-Merphos oxide||Not Assessed under the IRIS program.||||||
-Metalaxyl||Not Assessed under the IRIS program.||||||
-Methacrylonitrile||Not Assessed under the IRIS program.||||||
-Methamidophos||Not Assessed under the IRIS program.||||||
-Methanol||Not Assessed under the IRIS program.||||||
-Methidathion||Not Assessed under the IRIS program.||||||
-Methomyl||Not Assessed under the IRIS program.||||||
-Methoxychlor||Not Assessed under the IRIS program.||||||
--Methoxyethanol||Not Assessed under the IRIS program.||||||
-Methyl acrylate||Not Assessed under the IRIS program.||||||
-Methyl chloride||Not Assessed under the IRIS program.||||||
-Methyl chlorocarbonate||Not Assessed under the IRIS program.||||||
-Methyl ethyl ketone (MEK)||Not Assessed under the IRIS program.||||||
-Methyl iodide||Not Assessed under the IRIS program.||||||
-Methyl isobutyl ketone (MIBK)||Not Assessed under the IRIS program.||||||
-Methyl isocyanate||Not Assessed under the IRIS program.||||||
-Methyl methacrylate||Not Assessed under the IRIS program.||||||
-Methyl parathion||Not Assessed under the IRIS program.||||||
-Methyl tert-butyl ether (MTBE)||Not Assessed under the IRIS program.||||||
--(2-Methyl-4-chlorophenoxy) butyric acid (MCPB)||Not Assessed under the IRIS program.||||||
--(2-Methyl-4-chlorophenoxy)propionic acid (MCPP)||Not Assessed under the IRIS program.||||||
--Methyl-4-chlorophenoxyacetic acid (MCPA)||Not Assessed under the IRIS program.||||||
-Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI)||Not Assessed under the IRIS program.||||||
-,4'-Methylene bis(N,N'-dimethyl)aniline||Not Assessed under the IRIS program.||||||
-Methylmercury (MeHg)||Not Assessed under the IRIS program.||||||
--Methylnaphthalene||Not Assessed under the IRIS program.||||||
--Methylphenol||Not Assessed under the IRIS program.||||||
--Methylphenol||Not Assessed under the IRIS program.||||||
--Methylphenol||Not Assessed under the IRIS program.||||||
-Metolachlor||Not Assessed under the IRIS program.||||||
-Metribuzin||Not Assessed under the IRIS program.||||||
-Mirex||Not Assessed under the IRIS program.||||||
-Molinate||Not Assessed under the IRIS program.||||||
-Molybdenum||Not Assessed under the IRIS program.||||||
-Monochloramine||Not Assessed under the IRIS program.||||||
-Naled||Not Assessed under the IRIS program.||||||
-Naphthalene||Not Assessed under the IRIS program.||||||
-Napropamide||Not Assessed under the IRIS program.||||||
-Nickel carbonyl||Not Assessed under the IRIS program.||||||
-Nickel refinery dust||Not Assessed under the IRIS program.||||||
-Nickel subsulfide||Not Assessed under the IRIS program.||||||
-Nickel, soluble salts||Not Assessed under the IRIS program.||||||
-Nitrapyrin||Not Assessed under the IRIS program.||||||
-Nitrate||Not Assessed under the IRIS program.||||||
-Nitric oxide||Not Assessed under the IRIS program.||||||
-Nitrite||Not Assessed under the IRIS program.||||||
-Nitrobenzene||Not Assessed under the IRIS program.||||||
-Nitrogen dioxide||Not Assessed under the IRIS program.||||||
-Nitroguanidine||Not Assessed under the IRIS program.||||||
-p-Nitrophenol||Not Assessed under the IRIS program.||||||
--Nitropropane||Not Assessed under the IRIS program.||||||
-N-Nitroso-N-methylethylamine||Not Assessed under the IRIS program.||||||
-N-Nitroso-di-n-butylamine||Not Assessed under the IRIS program.||||||
-N-Nitrosodi-N-propylamine||Not Assessed under the IRIS program.||||||
-N-Nitrosodiethanolamine||Not Assessed under the IRIS program.||||||
-N-Nitrosodiethylamine||Not Assessed under the IRIS program.||||||
-N-Nitrosodimethylamine||Not Assessed under the IRIS program.||||||
-N-Nitrosodiphenylamine||Not Assessed under the IRIS program.||||||
-N-Nitrosopyrrolidine||Not Assessed under the IRIS program.||||||
-Nonabromodiphenyl ether||Not Assessed under the IRIS program.||||||
-Norflurazon||Not Assessed under the IRIS program.||||||
-NuStar||Not Assessed under the IRIS program.||||||
-Octabromodiphenyl ether||Not Assessed under the IRIS program.||||||
-Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX)||Not Assessed under the IRIS program.||||||
-Oryzalin||Not Assessed under the IRIS program.||||||
-Oxadiazon||Not Assessed under the IRIS program.||||||
-Oxamyl||Not Assessed under the IRIS program.||||||
-Oxyfluorfen||Not Assessed under the IRIS program.||||||
-Paclobutrazol||Not Assessed under the IRIS program.||||||
-Paraquat||Not Assessed under the IRIS program.||||||
-Parathion||Not Assessed under the IRIS program.||||||
-Pendimethalin||Not Assessed under the IRIS program.||||||
-Pentabromodiphenyl ether||Not Assessed under the IRIS program.||||||
-,2',4,4',5-Pentabromodiphenyl ether (BDE-99)||Not Assessed under the IRIS program.||||||
-Pentachlorobenzene||Not Assessed under the IRIS program.||||||
-Pentachlorocyclopentadiene||Not Assessed under the IRIS program.||||||
-Pentachloronitrobenzene (PCNB)||Not Assessed under the IRIS program.||||||
-Pentachlorophenol||Not Assessed under the IRIS program.||||||
-Pentafluoroethane||Not Assessed under the IRIS program.||||||
-Perchlorate (ClO4) and Perchlorate Salts||Not Assessed under the IRIS program.||||||
-Permethrin||Not Assessed under the IRIS program.||||||
-Phenanthrene||Not Assessed under the IRIS program.||||||
-Phenmedipham||Not Assessed under the IRIS program.||||||
-Phenol||Not Assessed under the IRIS program.||||||
-m-Phenylenediamine||Not Assessed under the IRIS program.||||||
-Phenylmercuric acetate||Not Assessed under the IRIS program.||||||
-Phosalone||Not Assessed under the IRIS program.||||||
-Phosgene||Not Assessed under the IRIS program.||||||
-Phosmet||Not Assessed under the IRIS program.||||||
-Phosphine||Not Assessed under the IRIS program.||||||
-Phosphoric acid||Not Assessed under the IRIS program.||||||
-Phthalic anhydride||Not Assessed under the IRIS program.||||||
-Picloram||Not Assessed under the IRIS program.||||||
-Pirimiphos-methyl||Not Assessed under the IRIS program.||||||
-Polychlorinated biphenyls (PCBs)||Not Assessed under the IRIS program.||||||
-Potassium cyanide||Not Assessed under the IRIS program.||||||
-Potassium silver cyanide||Not Assessed under the IRIS program.||||||
-Prochloraz||Not Assessed under the IRIS program.||||||
-Prometon||Not Assessed under the IRIS program.||||||
-Prometryn||Not Assessed under the IRIS program.||||||
-Pronamide||Not Assessed under the IRIS program.||||||
-Propachlor||Not Assessed under the IRIS program.||||||
-Propanil||Not Assessed under the IRIS program.||||||
-Propargite||Not Assessed under the IRIS program.||||||
-Propargyl alcohol||Not Assessed under the IRIS program.||||||
-Propazine||Not Assessed under the IRIS program.||||||
-Propham||Not Assessed under the IRIS program.||||||
-Propiconazole||Not Assessed under the IRIS program.||||||
-beta-Propiolactone||Not Assessed under the IRIS program.||||||
-Propionaldehyde||Not Assessed under the IRIS program.||||||
-Propylene glycol||Not Assessed under the IRIS program.||||||
-Propylene glycol monoethyl ether||Not Assessed under the IRIS program.||||||
-Propylene glycol monomethyl ether (PGME)||Not Assessed under the IRIS program.||||||
-Propylene oxide||Not Assessed under the IRIS program.||||||
-Propyleneimine||Not Assessed under the IRIS program.||||||
-Pursuit||Not Assessed under the IRIS program.||||||
-Pydrin||Not Assessed under the IRIS program.||||||
-Pyrene||Not Assessed under the IRIS program.||||||
-Pyridine||Not Assessed under the IRIS program.||||||
-Quinalphos||Not Assessed under the IRIS program.||||||
-Quinoline||Not Assessed under the IRIS program.||||||
-Quinone||Not Assessed under the IRIS program.||||||
-Radium 226,228||Not Assessed under the IRIS program.||||||
-Radon 222||Not Assessed under the IRIS program.||||||
-Refractory ceramic fibers||Not Assessed under the IRIS program.||||||
-Resmethrin||Not Assessed under the IRIS program.||||||
-Rotenone||Not Assessed under the IRIS program.||||||
-Savey||Not Assessed under the IRIS program.||||||
-Selenious acid||Not Assessed under the IRIS program.||||||
-Selenium and Compounds||Not Assessed under the IRIS program.||||||
-Selenium sulfide||Not Assessed under the IRIS program.||||||
-Selenourea||Not Assessed under the IRIS program.||||||
-Sethoxydim||Not Assessed under the IRIS program.||||||
-Silver||Not Assessed under the IRIS program.||||||
-Silver cyanide||Not Assessed under the IRIS program.||||||
-Simazine||Not Assessed under the IRIS program.||||||
-Sodium azide||Not Assessed under the IRIS program.||||||
-Sodium cyanide||Not Assessed under the IRIS program.||||||
-Sodium diethyldithiocarbamate||Not Assessed under the IRIS program.||||||
-Sodium fluoroacetate||Not Assessed under the IRIS program.||||||
-Strontium||Not Assessed under the IRIS program.||||||
-Strychnine||Not Assessed under the IRIS program.||||||
-Styrene||Not Assessed under the IRIS program.||||||
-Systhane||Not Assessed under the IRIS program.||||||
-Tebuthiuron||Not Assessed under the IRIS program.||||||
-Terbacil||Not Assessed under the IRIS program.||||||
-Terbutryn||Not Assessed under the IRIS program.||||||
-Tetrabromodiphenyl ether||Not Assessed under the IRIS program.||||||
-,2',4,4'-Tetrabromodiphenyl ether (BDE-47)||Not Assessed under the IRIS program.||||||
-,2,4,5-Tetrachlorobenzene||Not Assessed under the IRIS program.||||||
-Tetrachlorocyclopentadiene||Not Assessed under the IRIS program.||||||
-,3,7,8-Tetrachlorodibenzo-p-dioxin||Not Assessed under the IRIS program.||||||
-,1,1,2-Tetrachloroethane||Not Assessed under the IRIS program.||||||
-,1,2,2-Tetrachloroethane||Not Assessed under the IRIS program.||||||
-Tetrachloroethylene||Not Assessed under the IRIS program.||||||
-,3,4,6-Tetrachlorophenol||Not Assessed under the IRIS program.||||||
-Tetrachlorovinphos||Not Assessed under the IRIS program.||||||
-Tetraethyl lead||Not Assessed under the IRIS program.||||||
-Tetraethyldithiopyrophosphate||Not Assessed under the IRIS program.||||||
-,1,1,2-Tetrafluoroethane||Not Assessed under the IRIS program.||||||
-Tetrahydrofuran||Not Assessed under the IRIS program.||||||
-Thallium (I), soluble salts||Not Assessed under the IRIS program.||||||
-Thallium acetate||Not Assessed under the IRIS program.||||||
-Thallium carbonate||Not Assessed under the IRIS program.||||||
-Thallium chloride||Not Assessed under the IRIS program.||||||
-Thallium nitrate||Not Assessed under the IRIS program.||||||
-Thallium oxide||Not Assessed under the IRIS program.||||||
-Thallium selenite||Not Assessed under the IRIS program.||||||
-Thallium(I) sulfate||Not Assessed under the IRIS program.||||||
-Thiobencarb||Not Assessed under the IRIS program.||||||
-Thiophanate-methyl||Not Assessed under the IRIS program.||||||
-Thiram||Not Assessed under the IRIS program.||||||
-Toluene||Not Assessed under the IRIS program.||||||
-,4-/2,6-Toluene diisocyanate mixture (TDI)||Not Assessed under the IRIS program.||||||
-Toxaphene||Not Assessed under the IRIS program.||||||
-Tralomethrin||Not Assessed under the IRIS program.||||||
-Triallate||Not Assessed under the IRIS program.||||||
-Triasulfuron||Not Assessed under the IRIS program.||||||
-,2,4-Tribromobenzene||Not Assessed under the IRIS program.||||||
-Tribromochloromethane||Not Assessed under the IRIS program.||||||
-Tribromodiphenyl ether||Not Assessed under the IRIS program.||||||
-Tributyltin oxide (TBTO)||Not Assessed under the IRIS program.||||||
-,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113)||Not Assessed under the IRIS program.||||||
-Trichloroacetic acid||Not Assessed under the IRIS program.||||||
-,2,4-Trichlorobenzene||Not Assessed under the IRIS program.||||||
-Trichlorocyclopentadiene||Not Assessed under the IRIS program.||||||
-,1,2-Trichloroethane||Not Assessed under the IRIS program.||||||
-,1,1-Trichloroethane||Not Assessed under the IRIS program.||||||
-Trichloroethylene||Not Assessed under the IRIS program.||||||
-Trichlorofluoromethane||Not Assessed under the IRIS program.||||||
-,4,5-Trichlorophenol||Not Assessed under the IRIS program.||||||
-,4,6-Trichlorophenol||Not Assessed under the IRIS program.||||||
-(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP)||Not Assessed under the IRIS program.||||||
-,4,5-Trichlorophenoxyacetic acid (2,4,5-T)||Not Assessed under the IRIS program.||||||
-,1,2-Trichloropropane||Not Assessed under the IRIS program.||||||
-,2,3-Trichloropropane||Not Assessed under the IRIS program.||||||
-Tricresol||Not Assessed under the IRIS program.||||||
-Tridiphane||Not Assessed under the IRIS program.||||||
-Triethylamine||Not Assessed under the IRIS program.||||||
-Triethylene glycol monobutyl ether||Not Assessed under the IRIS program.||||||
-Triethylene glycol monoethyl ether||Not Assessed under the IRIS program.||||||
-Trifluralin||Not Assessed under the IRIS program.||||||
-,2,4-Trimethylpentane||Not Assessed under the IRIS program.||||||
-,3,5-Trinitrobenzene||Not Assessed under the IRIS program.||||||
-,4,6-Trinitrotoluene (TNT)||Not Assessed under the IRIS program.||||||
-Uranium, natural||Not Assessed under the IRIS program.||||||
-Uranium, soluble salts||Not Assessed under the IRIS program.||||||
-Urea||Not Assessed under the IRIS program.||||||
-Vanadium pentoxide||Not Assessed under the IRIS program.||||||
-Vernam||Not Assessed under the IRIS program.||||||
-Vinclozolin||Not Assessed under the IRIS program.||||||
-Vinyl acetate||Not Assessed under the IRIS program.||||||
-Vinyl bromide||Not Assessed under the IRIS program.||||||
-Vinyl chloride||Not Assessed under the IRIS program.||||||
-Warfarin||Not Assessed under the IRIS program.||||||
-White phosphorus||Not Assessed under the IRIS program.||||||
-Xylenes||Not Assessed under the IRIS program.||||||
-Zinc and Compounds||Not Assessed under the IRIS program.||||||
-Zinc cyanide||Not Assessed under the IRIS program.||||||
-Zinc phosphide||Not Assessed under the IRIS program.||||||
-Zineb||Not Assessed under the IRIS program.||||||
-</t2b>
-===Inhalation unit risks===
-<t2b index = "Substance,Observation type" locations = "CASRN,Precursor Effect/ Tumor Type,Extrapolation Method,Unit,Inhalation unit risks,Study Route,IRIS identifier" unit = "per µg /m<sup>3</sup>">
+* [[IRIS/Oral RfDs]]
-Acenaphthene|83-32-9|Not Assessed under the IRIS program.|||||
+* [[IRIS/Inhalation RfCs]]
-Acenaphthylene|208-96-8|Not Assessed under the IRIS program.|||||
+* [[IRIS/Weight-of-Evidence Characterizations]]
-Acephate|30560-19-1|Not Assessed under the IRIS program.|||||
+* [[IRIS/Inhalation unit risks]]
-Acetaldehyde|75-07-0|Nasal squamous cell carcinoma or adenocarcinoma|Linearized multistage-variable exposure input form (extra risk) |per µg/m<sup>3</sup>|2.2x10<sup>-6</sup>|Inhalation|
+* [[Template:IRIS links]]
-Acetochlor|34256-82-1|Not Assessed under the IRIS program.|||||
-Acetone|67-64-1|Not Assessed under the IRIS program.|||||
-Acetonitrile|75-05-8|Not Assessed under the IRIS program.|||||
-Acetophenone|98-86-2|Not Assessed under the IRIS program.|||||
-Acetyl chloride|75-36-5|Not Assessed under the IRIS program.|||||
-Acifluorfen, sodium|62476-59-9|Not Assessed under the IRIS program.|||||
-Acrolein|107-02-8|Not Assessed under the IRIS program.|||||
-Acrylamide|79-06-1|thyroid tumors and tunica vaginalis mesotheliomas|Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.|per µg /m<sup>3</sup>|1x10<sup>-4</sup>|Oral, drinking water|
-Acrylic acid|79-10-7|Not Assessed under the IRIS program.|||||
-Acrylonitrile|107-13-1|Respiratory cancer|Average relative risk|per µg /m<sup>3</sup>|6.8x10<sup>-5</sup>|Inhalation|
-Adiponitrile|111-69-3|Not Assessed under the IRIS program.|||||
-Alachlor|15972-60-8|Not Assessed under the IRIS program.|||||
-Alar|1596-84-5|Not Assessed under the IRIS program.|||||
-Aldicarb|116-06-3|Not Assessed under the IRIS program.|||||
-Aldicarb sulfone|1646-88-4|Not Assessed under the IRIS program.|||||
-Aldrin|309-00-2|Liver carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|4.9x10<sup>-3</sup>|Oral, Diet|
-Ally|74223-64-6|Not Assessed under the IRIS program.|||||
-Allyl alcohol|107-18-6|Not Assessed under the IRIS program.|||||
-Allyl chloride|107-05-1|Not Assessed under the IRIS program.|||||
-Aluminum phosphide|20859-73-8|Not Assessed under the IRIS program.|||||
-Amdro|67485-29-4|Not Assessed under the IRIS program.|||||
-Ametryn|834-12-8|Not Assessed under the IRIS program.|||||
--Aminopyridine|504-24-5|Not Assessed under the IRIS program.|||||
-Amitraz|33089-61-1|Not Assessed under the IRIS program.|||||
-Ammonia|7664-41-7|Not Assessed under the IRIS program.|||||
-Ammonium acetate|631-61-8|Not Assessed under the IRIS program.|||||
-Ammonium methacrylate|16325-47-6|Not Assessed under the IRIS program.|||||
-Ammonium sulfamate|7773-06-0|Not Assessed under the IRIS program.|||||
-Aniline|62-53-3|Not Assessed under the IRIS program.|||||
-ortho-Anisidine|90-04-0|Not Assessed under the IRIS program.|||||
-Anthracene|120-12-7|Not Assessed under the IRIS program.|||||
-Antimony|7440-36-0|Not Assessed under the IRIS program.|||||
-Antimony trioxide|1309-64-4|Not Assessed under the IRIS program.|||||
-Apollo|74115-24-5|Not Assessed under the IRIS program.|||||
-Aramite|140-57-8|Neoplastic liver nodules and carcinomas|Linearized multistage procedure, extra risk|per µg/m<sup>3</sup>|7.1x10<sup>-6</sup>|Oral, Diet|
-Aroclor 1016|12674-11-2|Not Assessed under the IRIS program.|||||
-Aroclor 1248|12672-29-6|Not Assessed under the IRIS program.|||||
-Aroclor 1254|11097-69-1|Not Assessed under the IRIS program.|||||
-Arsenic, inorganic|7440-38-2|Lung cancer|Absolute-risk linear model|per µg/m<sup>3</sup>|4.3x10<sup>-3</sup>|Inhalation, Occupational exposure|
-Arsine|7784-42-1|Not Assessed under the IRIS program.|||||
-Asbestos|1332-21-4|Lung cancer and mesothelioma|Additive risk of lung cancer and mesothelioma, using relative risk model for lung cancer and absolute risk model for mesothelioma|per f/mL|2.3x10<sup>-1</sup>|Inhalation, Occupational exposure|
-Assure|76578-14-8|Not Assessed under the IRIS program.|||||
-Asulam|3337-71-1|Not Assessed under the IRIS program.|||||
-Atrazine|1912-24-9|Not Assessed under the IRIS program.|||||
-Avermectin B1|65195-55-3|Not Assessed under the IRIS program.|||||
-Azobenzene|103-33-3|Abdominal cavity sarcomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.1x10<sup>-5</sup>|Oral, Diet|
-Barium and Compounds|7440-39-3|Not Assessed under the IRIS program.|||||
-Barium cyanide|542-62-1|Not Assessed under the IRIS program.|||||
-Baygon|114-26-1|Not Assessed under the IRIS program.|||||
-Bayleton|43121-43-3|Not Assessed under the IRIS program.|||||
-Baythroid|68359-37-5|Not Assessed under the IRIS program.|||||
-Benefin|1861-40-1|Not Assessed under the IRIS program.|||||
-Benomyl|17804-35-2|Not Assessed under the IRIS program.|||||
-Bentazon (Basagran)|25057-89-0|Not Assessed under the IRIS program.|||||
-Benz[a]anthracene|56-55-3|Not Assessed under the IRIS program.|||||
-Benzaldehyde|100-52-7|Not Assessed under the IRIS program.|||||
-Benzene|71-43-2|Leukemia|Low-dose linearity utilizing maximum likelihood estimates|per µg /m<sup>3</sup>|2.2x10<sup>-6</sup>|Inhalation|
-Benzene|71-43-2|Leukemia|Low-dose linearity utilizing maximum likelihood estimates|per µg /m<sup>3</sup>|7.8x10<sup>-6</sup>|Inhalation|
-Benzidine|92-87-5|Bladder tumors|One-hit with time factor, extra risk|per µg /m<sup>3</sup>|6.7x10<sup>-2</sup>|Inhalation, Occupational exposure|
-Benzo[a]pyrene (BaP)|50-32-8|Not Assessed under the IRIS program.|||||
-Benzo[b]fluoranthene|205-99-2|Not Assessed under the IRIS program.|||||
-Benzo[g,h,i]perylene|191-24-2|Not Assessed under the IRIS program.|||||
-Benzo[k]fluoranthene|207-08-9|Not Assessed under the IRIS program.|||||
-Benzoic acid|65-85-0|Not Assessed under the IRIS program.|||||
-Benzotrichloride|98-07-7|Not Assessed under the IRIS program.|||||
-Benzyl chloride|100-44-7|Not Assessed under the IRIS program.|||||
-Beryllium and compounds|7440-41-7|Lung cancer|Relative risk|per µg /m<sup>3</sup>|2.4x10<sup>-3</sup>|Inhalation, Occupational exposure|
-Bidrin|141-66-2|Not Assessed under the IRIS program.|||||
-Biphenthrin|82657-04-3|Not Assessed under the IRIS program.|||||
-,1-Biphenyl|92-52-4|Not Assessed under the IRIS program.|||||
-Bis(2-chloro-1-methylethyl) ether|108-60-1|Not Assessed under the IRIS program.|||||
-Bis(2-chloroethoxy)methane|111-91-1|Not Assessed under the IRIS program.|||||
-Bis(chloroethyl)ether (BCEE)|111-44-4|Hepatomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.3x10<sup>-4</sup>|Oral, Gavage followed by diet|
-Bis(chloromethyl)ether (BCME)|542-88-1|Respiratory tract tumors|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|6.2x10<sup>-2</sup>|Inhalation|
-Bisphenol A.|80-05-7|Not Assessed under the IRIS program.|||||
-Boron and Compounds|7440-42-8|Not Assessed under the IRIS program.|||||
-Bromate|15541-45-4|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-Brominated dibenzofurans|NA|Not Assessed under the IRIS program.|||||
-Bromobenzene|108-86-1|Not Assessed under the IRIS program.|||||
-Bromochloromethane|74-97-5|Not Assessed under the IRIS program.|||||
-Bromodichloromethane|75-27-4|Not Assessed under the IRIS program.|||||
-p-Bromodiphenyl ether|101-55-3|Not Assessed under the IRIS program.|||||
-Bromoform|75-25-2|Neoplastic lesions in the large intestine|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.1x10<sup>-6</sup>|Oral, Gavage in corn oil|
-Bromomethane|74-83-9|Not Assessed under the IRIS program.|||||
-Bromotrichloromethane|75-62-7|Not Assessed under the IRIS program.|||||
-Bromoxynil|1689-84-5|Not Assessed under the IRIS program.|||||
-Bromoxynil octanoate|1689-99-2|Not Assessed under the IRIS program.|||||
-,3-Butadiene|106-99-0|Leukemia|Linear extrapolation from LEC01 (0.254 ppm); LEC01 derived from linear relative rate model (RR = 1 + (B)(x)) using lifetable analysis with leukemia incidence data; an adjustment factor of 2 was applied.|per µg /m<sup>3</sup>|3x10<sup>-5</sup>|Inhalation|
-n-Butanol|71-36-3|Not Assessed under the IRIS program.|||||
-Butyl benzyl phthalate|85-68-7|Not Assessed under the IRIS program.|||||
-Butylate|2008-41-5|Not Assessed under the IRIS program.|||||
-t-Butylchloride|507-20-0|Not Assessed under the IRIS program.|||||
-Butylphthalyl butylglycolate (BPBG)|85-70-1|Not Assessed under the IRIS program.|||||
-Cacodylic acid|75-60-5|Not Assessed under the IRIS program.|||||
-Cadmium|7440-43-9|Lung, trachea, bronchus cancer deaths|Two stage; only first affected by exposure; extra risk|per µg /m<sup>3</sup>|1.8x10<sup>-3</sup>|Inhalation, Exposure in the workplace|
-Calcium cyanide|592-01-8|Not Assessed under the IRIS program.|||||
-Caprolactam|105-60-2|Not Assessed under the IRIS program.|||||
-Captafol|2425-06-1|Not Assessed under the IRIS program.|||||
-Captan|133-06-2|Not Assessed under the IRIS program.|||||
-Carbary|l63-25-2|Not Assessed under the IRIS program.|||||
-Carbofuran1|563-66-2|Not Assessed under the IRIS program.|||||
-Carbon disulfide|75-15-0|Not Assessed under the IRIS program.|||||
-Carbon tetrachloride|56-23-5|Pheochromocytoma|Log-probit model with linear extrapolation from the POD (LEC10).|per µg /m<sup>3</sup>|6x10<sup>-6</sup>|Inhalation|
-Carbonyl sulfide|463-58-1|Not Assessed under the IRIS program.|||||
-Carbosulfan|55285-14-8|Not Assessed under the IRIS program.|||||
-Carboxin|5234-68-4|Not Assessed under the IRIS program.|||||
-Cerium Oxide and Cerium Compounds|1306-38-3|Not Assessed under the IRIS program.|||||
-Chloral hydrate|302-17-0|Not Assessed under the IRIS program.|||||
-Chloramben|133-90-4|Not Assessed under the IRIS program.|||||
-Chlordane (Technical)|12789-03-6|Hepatocellular carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1x10<sup>-4<7sup>|Oral, Diet|
-Chlordecone (Kepone)|143-50-0|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-Chlorimuron-ethyl|90982-32-4|Not Assessed under the IRIS program.|||||
-Chlorine|7782-50-5|Not Assessed under the IRIS program.|||||
-Chlorine cyanide|506-77-4|Not Assessed under the IRIS program.|||||
-Chlorine dioxide|10049-04-4|Not Assessed under the IRIS program.|||||
-Chlorite (sodium salt)|7758-19-2|Not Assessed under the IRIS program.|||||
--Chloro-1,1-difluoroethane|75-68-3|Not Assessed under the IRIS program.|||||
--Chloroacetophenone|532-27-4|Not Assessed under the IRIS program.|||||
-p-Chloroaniline|106-47-8|Not Assessed under the IRIS program.|||||
-Chlorobenzene|108-90-7|Not Assessed under the IRIS program.|||||
-Chlorobenzilate|510-15-6|Not Assessed under the IRIS program.|||||
--Chlorobutane|109-69-3|Not Assessed under the IRIS program.|||||
--Chlorobutane|78-86-4|Not Assessed under the IRIS program.|||||
-Chlorocyclopentadiene|41851-50-7|Not Assessed under the IRIS program.|||||
-Chlorodifluoromethane|75-45-6|Not Assessed under the IRIS program.|||||
-Chloroform|67-66-3|Hepatocellular carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|2.3x10<sup>-5</sup>|Oral, Gavage|
-Chloromethyl methyl ether (CMME)|107-30-2|Not Assessed under the IRIS program.|||||
-beta-Chloronaphthalene|91-58-7|Not Assessed under the IRIS program.|||||
--Chlorophenol|95-57-8|Not Assessed under the IRIS program.|||||
-p-Chlorophenyl methyl sulfide|123-09-1|Not Assessed under the IRIS program.|||||
-p-Chlorophenyl methyl sulfone|98-57-7|Not Assessed under the IRIS program.|||||
-p-Chlorophenyl methyl sulfoxide|934-73-6|Not Assessed under the IRIS program.|||||
-Chloroprene|126-99-8|alveolar/ bronchiolar adenoma or carcinoma; hemangioma/ hemangiosarcoma (all organs); mammary gland adenocarcinoma, carcinoma, or adenoacanthoma; forestomach squamous cell papilloma or carcinoma; hepatocellular adenoma or carcinoma; Harderian gland adenoma or carcinoma; skin sarcoma; and Zymbal's gland carcinoma|Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.|per µg /m<sup>3</sup>|3x10<sup>-4</sup>|Inhalation|
-Chlorothalonil|1897-45-6|Not Assessed under the IRIS program.|||||
-o-Chlorotoluene|95-49-8|Not Assessed under the IRIS program.|||||
-Chlorpropham|101-21-3|Not Assessed under the IRIS program.|||||
-Chlorpyrifos|2921-88-2|Not Assessed under the IRIS program.|||||
-Chlorsulfuron|64902-72-3|Not Assessed under the IRIS program.|||||
-Chromium(III), insoluble salts|16065-83-1|Not Assessed under the IRIS program.|||||
-Chromium(VI)|18540-29-9|Lung cancer|Multistage, extra risk|per µg /m<sup>3</sup>|1.2x10<sup>-2</sup>|Inhalation, Occupational exposure|
-Chrysene|218-01-9|Not Assessed under the IRIS program.|||||
-Coke oven emissions|8007-45-2|Respiratory cancer|Linearized multistage procedure|per µg /m<sup>3</sup>|6.2x10<sup>-4</sup>|Inhalation, Occupational|
-Copper|7440-50-8|Not Assessed under the IRIS program.|||||
-Copper cyanide|544-92-3|Not Assessed under the IRIS program.|||||
-Creosote|8001-58-9|Not Assessed under the IRIS program.|||||
-Crotonaldehyde|123-73-9|Not Assessed under the IRIS program.|||||
-Cumene|98-82-8|Not Assessed under the IRIS program.|||||
-Cyanazine|21725-46-2|Not Assessed under the IRIS program.|||||
-Cyanide, free|57-12-5|Not Assessed under the IRIS program.|||||
-Cyanogen|460-19-5|Not Assessed under the IRIS program.|||||
-Cyanogen bromide|506-68-3|Not Assessed under the IRIS program.|||||
-Cyclohexane|110-82-7|Not Assessed under the IRIS program.|||||
-Cyclohexanone|108-94-1|Not Assessed under the IRIS program.|||||
-Cyclohexylamine|108-91-8|Not Assessed under the IRIS program.|||||
-Cyhalothrin/Karate|68085-85-8|Not Assessed under the IRIS program.|||||
-Cypermethrin|52315-07-8|Not Assessed under the IRIS program.|||||
-Cyromazine|66215-27-8|Not Assessed under the IRIS program.|||||
-Dacthal|1861-32-1|Not Assessed under the IRIS program.|||||
-Dalapon, sodium salt|75-99-0|Not Assessed under the IRIS program.|||||
-Danitol|39515-41-8|Not Assessed under the IRIS program.|||||
-,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209)|1163-19-5|Not Assessed under the IRIS program.|||||
-Demeton|8065-48-3|Not Assessed under the IRIS program.|||||
-Di (2-ethylhexyl)phthalate (DEHP)|117-81-7|Not Assessed under the IRIS program.|||||
-Di(2-ethylhexyl)adipate|103-23-1|Not Assessed under the IRIS program.|||||
-,4-Diaminotoluene|95-80-7|Not Assessed under the IRIS program.|||||
-Diazomethane|334-88-3|Not Assessed under the IRIS program.|||||
-Dibenz[a,h]anthracene|53-70-3|Not Assessed under the IRIS program.|||||
-Dibenzofuran|132-64-9|Not Assessed under the IRIS program.|||||
-,2-Dibromo-3-chloropropane (DBCP)|96-12-8|Not Assessed under the IRIS program.|||||
-,4-Dibromobenzene|106-37-6|Not Assessed under the IRIS program.|||||
-Dibromochloromethane|124-48-1|Not Assessed under the IRIS program.|||||
-Dibromodichloromethane|594-18-3|Not Assessed under the IRIS program.|||||
-p,p'-Dibromodiphenyl ether|2050-47-7|Not Assessed under the IRIS program.|||||
-,2-Dibromoethane|106-93-4|Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas|Multistage-Weibull model; linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range.|per µg /m<sup>3</sup>|6x10<sup>-4</sup>|Inhalation|
-,2-Dibromoethane|106-93-4|Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas|Multistage-Weibull model; linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range.|per µg /m<sup>3</sup>|3x10<sup>-4</sup>|Inhalation|
-Dibutyl phthalate|84-74-2|Not Assessed under the IRIS program.|||||
-Dicamba|1918-00-9|Not Assessed under the IRIS program.|||||
-Dichloroacetic acid|79-43-6|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-,3-Dichlorobenzene|541-73-1|Not Assessed under the IRIS program.|||||
-,4-Dichlorobenzene|106-46-7|Not Assessed under the IRIS program.|||||
-,2-Dichlorobenzene|95-50-1|Not Assessed under the IRIS program.|||||
-,3'-Dichlorobenzidine|91-94-1|Not Assessed under the IRIS program.|||||
-Dichlorodifluoromethane|75-71-8|Not Assessed under the IRIS program.|||||
-p,p'-Dichlorodiphenyl dichloroethane (DDD)|72-54-8|Not Assessed under the IRIS program.|||||
-p,p'-Dichlorodiphenyldichloroethylene (DDE)|72-55-9|Not Assessed under the IRIS program.|||||
-p,p'-Dichlorodiphenyltrichloroethane (DDT)|50-29-3|Liver tumors, benign and malignant|Linear multistage procedure, extra risk|per µg /m<sup>3</sup>|9.7x10<sup>-5</sup>|Oral,Diet|
-,2-Dichloroethane|107-06-2|Hemangiosarcomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|2.6x10<sup>-5</sup>|Oral,Gavage|
-,1-Dichloroethane|75-34-3|Not Assessed under the IRIS program.|||||
-trans-1,2-Dichloroethylene|156-60-5|Not Assessed under the IRIS program.|||||
-cis-1,2-Dichloroethylene|156-59-2|Not Assessed under the IRIS program.|||||
-,1-Dichloroethylene (1,1-DCE)|75-35-4|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-Dichloromethane|75-09-2|Hepatocellular carcinomas or adenomas, bronchoalveolar carcinomas or adenomas|Multistage model with linear extrapolation from the point of departure (BMDL10)|per µg /m<sup>3</sup>|1x10<sup>-8</sup>|Inhalation|
-,4-Dichlorophenol|120-83-2|Not Assessed under the IRIS program.|||||
--(2,4-Dichlorophenoxy)butyric acid (2,4-DB)|94-82-6|Not Assessed under the IRIS program.|||||
-,4-Dichlorophenoxyacetic acid (2,4-D)|94-75-7|Not Assessed under the IRIS program.|||||
-,2-Dichloropropane|78-87-5|Not Assessed under the IRIS program.|||||
-,3-Dichloropropanol|616-23-9|Not Assessed under the IRIS program.|||||
-,3-Dichloropropene|542-75-6|Bronchioalveolar adenoma|Linearized multistage model, extra risk|per µg /m<sup>3</sup>|4x10<sup>-6</sup>|Inhalation|
-Dichlorvos|62-73-7|Not Assessed under the IRIS program.|||||
-Dicofol|115-32-2|Not Assessed under the IRIS program.|||||
-Dieldrin|60-57-1|Liver carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|4.6x10<sup>-3</sup>|Oral, Diet|
-Diesel engine exhaust|NA|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-Diethyl phthalate|84-66-2|Not Assessed under the IRIS program.|||||
-Diethyl sulfate|64-67-5|Not Assessed under the IRIS program.|||||
-Diethyl-p-nitrophenylphosphate|311-45-5|Not Assessed under the IRIS program.|||||
-Diethylene glycol dinitrate (DEGDN)|693-21-0|Not Assessed under the IRIS program.|||||
-Difenzoquat|43222-48-6|Not Assessed under the IRIS program.|||||
-Diflubenzuron|35367-38-5|Not Assessed under the IRIS program.|||||
-,1-Difluoroethane|75-37-6|Not Assessed under the IRIS program.|||||
-Diisopropyl methylphosphonate (DIMP)|1445-75-6|Not Assessed under the IRIS program.|||||
-Dimethipin|55290-64-7|Not Assessed under the IRIS program.|||||
-Dimethoate|60-51-5|Not Assessed under the IRIS program.|||||
-Dimethyl phthalate|131-11-3|Not Assessed under the IRIS program.|||||
-Dimethyl sulfate|77-78-1|Not Assessed under the IRIS program.|||||
-Dimethyl terephthalate (DMT)|120-61-6|Not Assessed under the IRIS program.|||||
-Dimethylamine|124-40-3|Not Assessed under the IRIS program.|||||
-N-N-Dimethylaniline|121-69-7|Not Assessed under the IRIS program.|||||
-,3-Dimethylbenzidine|119-93-7|Not Assessed under the IRIS program.|||||
-N,N-Dimethylformamide|68-12-2|Not Assessed under the IRIS program.|||||
-,4-Dimethylphenol|95-65-8|Not Assessed under the IRIS program.|||||
-,6-Dimethylphenol|576-26-1|Not Assessed under the IRIS program.|||||
-,4-Dimethylphenol|105-67-9|Not Assessed under the IRIS program.|||||
-,6-Dinitro-o-cyclohexyl phenol|131-89-5|Not Assessed under the IRIS program.|||||
-m-Dinitrobenzene|99-65-0|Not Assessed under the IRIS program.|||||
-o-Dinitrobenzene|528-29-0|Not Assessed under the IRIS program.|||||
-,4-Dinitrophenol|51-28-5|Not Assessed under the IRIS program.|||||
-,4-Dinitrotoluene|121-14-2|Not Assessed under the IRIS program.|||||
-,4-/2,6-Dinitrotoluene mixture|NA|Not Assessed under the IRIS program.|||||
-Dinoseb|88-85-7|Not Assessed under the IRIS program.|||||
-,4-Dioxane|123-91-1|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-Diphenamid|957-51-7|Not Assessed under the IRIS program.|||||
-Diphenylamine|122-39-4|Not Assessed under the IRIS program.|||||
-,2-Diphenylhydrazine|122-66-7|Hepatocellular carcinomas and neoplastic liver nodules|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|2.2x10<sup>-4</sup>|Oral, Diet|
-Diquat|85-00-7|Not Assessed under the IRIS program.|||||
-Disulfoton|298-04-4|Not Assessed under the IRIS program.|||||
-,4-Dithiane|505-29-3|Not Assessed under the IRIS program.|||||
-Diuron|330-54-1|Not Assessed under the IRIS program.|||||
-Dodine|2439-10-3|Not Assessed under the IRIS program.|||||
-Endosulfan|115-29-7|Not Assessed under the IRIS program.|||||
-Endothall|145-73-3|Not Assessed under the IRIS program.|||||
-Endrin|72-20-8|Not Assessed under the IRIS program.|||||
-Epichlorohydrin|106-89-8|Nasal cavity tumors|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.2x10<sup>-6</sup>|Inhalation|
-,2-Epoxybutane (EBU)|106-88-7|Not Assessed under the IRIS program.|||||
-Ethephon|16672-87-0|Not Assessed under the IRIS program.|||||
-Ethion|563-12-2|Not Assessed under the IRIS program.|||||
--Ethoxyethanol|110-80-5|Not Assessed under the IRIS program.|||||
-Ethyl acetate|141-78-6|Not Assessed under the IRIS program.|||||
-Ethyl carbamate|51-79-6|Not Assessed under the IRIS program.|||||
-Ethyl chloride|75-00-3|Not Assessed under the IRIS program.|||||
-S-Ethyl dipropylthiocarbamate (EPTC)|759-94-4|Not Assessed under the IRIS program.|||||
-Ethyl ether|60-29-7|Not Assessed under the IRIS program.|||||
-Ethyl p-nitrophenyl phenylphosphorothioate (EPN)|2104-64-5|Not Assessed under the IRIS program.|||||
-Ethylbenzene|100-41-4|Not Assessed under the IRIS program.|||||
-Ethylene diamine|107-15-3|Not Assessed under the IRIS program.|||||
-Ethylene glycol|107-21-1|Not Assessed under the IRIS program.|||||
-Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol)|111-76-2|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-Ethylene thiourea (ETU)|96-45-7|Not Assessed under the IRIS program.|||||
-Ethyleneimine|151-56-4|Not Assessed under the IRIS program.|||||
-Ethylphthalyl ethylglycolate (EPEG)|84-72-0|Not Assessed under the IRIS program.|||||
-Express|101200-48-0|Not Assessed under the IRIS program.|||||
-Fenamiphos|22224-92-6|Not Assessed under the IRIS program.|||||
-Fluometuron|2164-17-2|Not Assessed under the IRIS program.|||||
-Fluoranthene|206-44-0|Not Assessed under the IRIS program.|||||
-Fluorene|86-73-7|Not Assessed under the IRIS program.|||||
-Fluorine (soluble fluoride)|7782-41-4|Not Assessed under the IRIS program.|||||
-Fluridone|59756-60-4|Not Assessed under the IRIS program.|||||
-Flurprimidol|56425-91-3|Not Assessed under the IRIS program.|||||
-Flutolanil|66332-96-5|Not Assessed under the IRIS program.|||||
-Fluvalinate|69409-94-5|Not Assessed under the IRIS program.|||||
-Folpet|133-07-3|Not Assessed under the IRIS program.|||||
-Fomesafen|72178-02-0|Not Assessed under the IRIS program.|||||
-Fonofos|944-22-9|Not Assessed under the IRIS program.|||||
-Formaldehyde|50-00-0|Squamous cell carcinoma|Linearized multistage procedure, additional risk|per µg /m<sup>3</sup>|1.3x10<sup>-5</sup>|Inhalation|
-Formic acid|64-18-6|Not Assessed under the IRIS program.|||||
-Fosetyl-al|39148-24-8|Not Assessed under the IRIS program.|||||
-Furan|110-00-9|Not Assessed under the IRIS program.|||||
-Furfural|98-01-1|Not Assessed under the IRIS program.|||||
-Furmecyclox|60568-05-0|Not Assessed under the IRIS program.|||||
-Glufosinate-ammonium|77182-82-2|Not Assessed under the IRIS program.|||||
-Glycidaldehyde|765-34-4|Not Assessed under the IRIS program.|||||
-Glyphosate|1071-83-6|Not Assessed under the IRIS program.|||||
-Haloxyfop-methyl|69806-40-2|Not Assessed under the IRIS program.|||||
-Harmony|79277-27-3|Not Assessed under the IRIS program.|||||
-Heptachlor|76-44-8|Hepatocellular carcinomas|Linearized multistage procedure, extra risk |per µg/m<sup>3</sup>|1.3x10<sup>-3</sup>|Oral, Diet|
-Heptachlor epoxide|1024-57-3|Hepatocellular carcinomas|Linearized multistage procedure, extra risk|per µg/m<sup>3</sup>|2.6x10<sup>-3</sup>|Oral, Diet|
-n-Heptane|142-82-5|Not Assessed under the IRIS program.|||||
-Hexabromobenzene|87-82-1|Not Assessed under the IRIS program.|||||
-Hexabromodiphenyl ether|36483-60-0|Not Assessed under the IRIS program.|||||
-,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153)|68631-49-2|Not Assessed under the IRIS program.|||||
-Hexachlorobenzene|118-74-1|Hepatocellular carcinoma|Linearized multistage, extra risk|per µg /m<sup>3</sup>|4.6x10<sup>-4</sup>|Oral, Diet|
-Hexachlorobutadiene|87-68-3|Renal tubular adenomas and adenocarcinomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|2.2x10<sup>-5</sup>|Oral, Diet|
-alpha-Hexachlorocyclohexane (alpha-HCH)|319-84-6|Hepatic nodules and hepatocellular carcinomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.8x10<sup>-3</sup>|Oral, Diet|
-beta-Hexachlorocyclohexane (beta-HCH)|319-85-7|Hepatic nodules and hepatocellular carcinomas|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|5.3x10<sup>-4</sup>|Oral, Diet|
-delta-Hexachlorocyclohexane (delta-HCH)|319-86-8|Not Assessed under the IRIS program.|||||
-epsilon-Hexachlorocyclohexane (epsilon-HC)|6108-10-7|Not Assessed under the IRIS program.|||||
-gamma-Hexachlorocyclohexane (gamma-HCH)|58-89-9|Not Assessed under the IRIS program.|||||
-technical Hexachlorocyclohexane (t-HCH)|608-73-1|Liver nodules and hepatocellular carcinomas|Linearized multistage procedure|per µg /m<sup>3</sup>|5.1x10<sup>-4</sup>|Oral, Diet|
-Hexachlorocyclopentadiene (HCCPD)|77-47-4|Not Assessed under the IRIS program.|||||
-Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD|57653-85-7|Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas)|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.3|Oral, Gavage|
-Hexachloroethane|67-72-1|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-Hexachlorophene|70-30-4|Not Assessed under the IRIS program.|||||
-Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)|121-82-4|Not Assessed under the IRIS program.|||||
-,6-Hexamethylene diisocyanate|822-06-0|Not Assessed under the IRIS program.|||||
-n-Hexane|110-54-3|Not Assessed under the IRIS program.|||||
--Hexanone|591-78-6|Not Assessed under the IRIS program.|||||
-Hexazinone|51235-04-2|Not Assessed under the IRIS program.|||||
-Hydrazine/Hydrazine sulfate|302-01-2|Nasal cavity adenoma or adenocarcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|4.9x10<sup>-3</sup>|Inhalation|
-Hydrogen Cyanide and Cyanide Salts|Various|Not Assessed under the IRIS program.|||||
-Hydrogen chloride|7647-01-0|Not Assessed under the IRIS program.|||||
-Hydrogen sulfide|7783-06-4|Not Assessed under the IRIS program.|||||
-Hydroquinone|123-31-9|Not Assessed under the IRIS program.|||||
-Imazalil|35554-44-0|Not Assessed under the IRIS program.|||||
-Imazaquin|81335-37-7|Not Assessed under the IRIS program.|||||
-Indeno[1,2,3-cd]pyrene|193-39-5|Not Assessed under the IRIS program.|||||
-Iprodione|36734-19-7|Not Assessed under the IRIS program.|||||
-Isobutyl alcohol|78-83-1|Not Assessed under the IRIS program.|||||
-Isophorone|78-59-1|Not Assessed under the IRIS program.|||||
-Isopropalin|33820-53-0|Not Assessed under the IRIS program.|||||
-Isopropyl methyl phosphonic acid (IMPA)|1832-54-8|Not Assessed under the IRIS program.|||||
-Isoxaben|82558-50-7|Not Assessed under the IRIS program.|||||
-Lactofen|77501-63-4|Not Assessed under the IRIS program.|||||
-Lead and compounds (inorganic)|7439-92-1|Not Assessed under the IRIS program.|||||
-d-Limonene|5989-27-5|Not Assessed under the IRIS program.|||||
-Linuron|330-55-2|Not Assessed under the IRIS program.|||||
-Londax|83055-99-6|Not Assessed under the IRIS program.|||||
-Malathion|121-75-5|Not Assessed under the IRIS program.|||||
-Maleic anhydride|108-31-6|Not Assessed under the IRIS program.|||||
-Maleic hydrazide|123-33-1|Not Assessed under the IRIS program.|||||
-Maneb|12427-38-2|Not Assessed under the IRIS program.|||||
-Manganese|7439-96-5|Not Assessed under the IRIS program.|||||
-Mepiquat chloride|24307-26-4|Not Assessed under the IRIS program.|||||
-Mercuric chloride (HgCl2)|7487-94-7|Not Assessed under the IRIS program.|||||
-Mercury, elemental|7439-97-6|Not Assessed under the IRIS program.|||||
-Merphos|150-50-5|Not Assessed under the IRIS program.|||||
-Merphos oxide|78-48-8|Not Assessed under the IRIS program.|||||
-Metalaxyl|57837-19-1|Not Assessed under the IRIS program.|||||
-Methacrylonitrile|126-98-7|Not Assessed under the IRIS program.|||||
-Methamidophos|10265-92-6|Not Assessed under the IRIS program.|||||
-Methanol|67-56-1|Not Assessed under the IRIS program.|||||
-Methidathion|950-37-8|Not Assessed under the IRIS program.|||||
-Methomyl|16752-77-5|Not Assessed under the IRIS program.|||||
-Methoxychlor|72-43-5|Not Assessed under the IRIS program.|||||
--Methoxyethanol|109-86-4|Not Assessed under the IRIS program.|||||
-Methyl acrylate|96-33-3|Not Assessed under the IRIS program.|||||
-Methyl chloride|74-87-3|Not Assessed under the IRIS program.|||||
-Methyl chlorocarbonate|79-22-1|Not Assessed under the IRIS program.|||||
-Methyl ethyl ketone (MEK)|78-93-3|Not Assessed under the IRIS program.|||||
-Methyl iodide|74-88-4|Not Assessed under the IRIS program.|||||
-Methyl isobutyl ketone (MIBK)|108-10-1|Not Assessed under the IRIS program.|||||
-Methyl isocyanate|624-83-9|Not Assessed under the IRIS program.|||||
-Methyl methacrylate|80-62-6|Not Assessed under the IRIS program.|||||
-Methyl parathion|298-00-0|Not Assessed under the IRIS program.|||||
-Methyl tert-butyl ether (MTBE)|1634-04-4|Not Assessed under the IRIS program.|||||
--(2-Methyl-4-chlorophenoxy) butyric acid (MCPB)|94-81-5|Not Assessed under the IRIS program.|||||
--(2-Methyl-4-chlorophenoxy)propionic acid (MCPP)|93-65-2|Not Assessed under the IRIS program.|||||
--Methyl-4-chlorophenoxyacetic acid (MCPA)|94-74-6|Not Assessed under the IRIS program.|||||
-Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI)|101-68-8|Not Assessed under the IRIS program.|||||
-,4'-Methylene bis(N,N'-dimethyl)aniline|101-61-1|Not Assessed under the IRIS program.|||||
-Methylmercury (MeHg)|22967-92-6|Not Assessed under the IRIS program.|||||
--Methylnaphthalene|91-57-6|Not Assessed under the IRIS program.|||||
--Methylphenol|95-48-7|Not Assessed under the IRIS program.|||||
--Methylphenol|106-44-5|Not Assessed under the IRIS program.|||||
--Methylphenol|108-39-4|Not Assessed under the IRIS program.|||||
-Metolachlor|51218-45-2|Not Assessed under the IRIS program.|||||
-Metribuzin|21087-64-9|Not Assessed under the IRIS program.|||||
-Mirex|2385-85-5|Not Assessed under the IRIS program.|||||
-Molinate|2212-67-1|Not Assessed under the IRIS program.|||||
-Molybdenum|7439-98-7|Not Assessed under the IRIS program.|||||
-Monochloramine|10599-90-3|Not Assessed under the IRIS program.|||||
-Naled|300-76-5|Not Assessed under the IRIS program.|||||
-Naphthalene|91-20-3|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-Napropamide|15299-99-7|Not Assessed under the IRIS program.|||||
-Nickel carbonyl|13463-39-3|Not Assessed under the IRIS program.|||||
-Nickel refinery dust|NA|Lung cancer|Additive and multiplicative|per µg /m<sup>3</sup>|2.4x10-4|Inhalation|
-Nickel subsulfide|12035-72-2|Lung cancer|Additive and multiplicative|per µg /m<sup>3</sup>|4.8x10<sup>-4</sup>|Inhalation|
-Nickel, soluble salts|NA|Not Assessed under the IRIS program.|||||
-Nitrapyrin|1929-82-4|Not Assessed under the IRIS program.|||||
-Nitrate|14797-55-8|Not Assessed under the IRIS program.|||||
-Nitric oxide|10102-43-9|Not Assessed under the IRIS program.|||||
-Nitrite|14797-65-0|Not Assessed under the IRIS program.|||||
-Nitrobenzene|98-95-3|Liver hepatocellular adenomas or carcinomas, kidney tubular adenomas or carcinomas, thyroid follicular cell adenomas or carcinomas|Multistage model with linear extrapolation from the POD (LEC10).|per µg /m<sup>3</sup>|4x10<sup>-5</sup>|Inhalation|
-Nitrogen dioxide|10102-44-0|Not Assessed under the IRIS program.|||||
-Nitroguanidine|556-88-7|Not Assessed under the IRIS program.|||||
-p-Nitrophenol|100-02-7|Not Assessed under the IRIS program.|||||
--Nitropropane|79-46-9|Not Assessed under the IRIS program.|||||
-N-Nitroso-N-methylethylamine|10595-95-6|Not Assessed under the IRIS program.|||||
-N-Nitroso-di-n-butylamine|924-16-3|Bladder and esophagus tumors|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.6x10<sup>-3</sup>|Oral, Drinking water|
-N-Nitrosodi-N-propylamine|621-64-7|Not Assessed under the IRIS program.|||||
-N-Nitrosodiethanolamine|1116-54-7|Not Assessed under the IRIS program.|||||
-N-Nitrosodiethylamine|55-18-5|Liver tumors|Weibull, extra risk|per µg /m<sup>3</sup>|4.3x10<sup>-2</sup>|Oral, Drinking water|
-N-Nitrosodimethylamine|62-75-9|Liver tumors|Weibull, extra risk|per µg /m<sup>3</sup>|1.4x10<sup>-2</sup>|Oral, Drinking water|
-N-Nitrosodiphenylamine|86-30-6|Not Assessed under the IRIS program.|||||
-N-Nitrosopyrrolidine|930-55-2|Hepatocellular carcinoma and adenoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|6.1x10<sup>-4</sup>|Oral, Diet|
-Nonabromodiphenyl ether|63936-56-1|Not Assessed under the IRIS program.|||||
-Norflurazon|27314-13-2|Not Assessed under the IRIS program.|||||
-NuStar|85509-19-9|Not Assessed under the IRIS program.|||||
-Octabromodiphenyl ether|32536-52-0|Not Assessed under the IRIS program.|||||
-Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX)|2691-41-0|Not Assessed under the IRIS program.|||||
-Oryzalin|19044-88-3|Not Assessed under the IRIS program.|||||
-Oxadiazon|19666-30-9|Not Assessed under the IRIS program.|||||
-Oxamyl|23135-22-0|Not Assessed under the IRIS program.|||||
-Oxyfluorfen|42874-03-3|Not Assessed under the IRIS program.|||||
-Paclobutrazol|76738-62-0|Not Assessed under the IRIS program.|||||
-Paraquat|1910-42-5|Not Assessed under the IRIS program.|||||
-Parathion|56-38-2|Not Assessed under the IRIS program.|||||
-Pendimethalin|40487-42-1|Not Assessed under the IRIS program.|||||
-Pentabromodiphenyl ether|32534-81-9|Not Assessed under the IRIS program.|||||
-,2',4,4',5-Pentabromodiphenyl ether (BDE-99)|60348-60-9|Not Assessed under the IRIS program.|||||
-Pentachlorobenzene|608-93-5|Not Assessed under the IRIS program.|||||
-Pentachlorocyclopentadiene|25329-35-5|Not Assessed under the IRIS program.|||||
-Pentachloronitrobenzene (PCNB)|82-68-8|Not Assessed under the IRIS program.|||||
-Pentachlorophenol|87-86-5|Not Assessed under the IRIS program.|||||
-Pentafluoroethane|354-33-6|Not Assessed under the IRIS program.|||||
-Perchlorate (ClO4) and Perchlorate Salts|7790-98-9|Not Assessed under the IRIS program.|||||
-Permethrin|52645-53-1|Not Assessed under the IRIS program.|||||
-Phenanthrene|85-01-8|Not Assessed under the IRIS program.|||||
-Phenmedipham|13684-63-4|Not Assessed under the IRIS program.|||||
-Phenol|108-95-2|Not Assessed under the IRIS program.|||||
-m-Phenylenediamine|108-45-2|Not Assessed under the IRIS program.|||||
-Phenylmercuric acetate|62-38-4|Not Assessed under the IRIS program.|||||
-Phosalone|2310-17-0|Not Assessed under the IRIS program.|||||
-Phosgene|75-44-5|Not Assessed under the IRIS program.|||||
-Phosmet|732-11-6|Not Assessed under the IRIS program.|||||
-Phosphine|7803-51-2|Not Assessed under the IRIS program.|||||
-Phosphoric acid|7664-38-2|Not Assessed under the IRIS program.|||||
-Phthalic anhydride|85-44-9|Not Assessed under the IRIS program.|||||
-Picloram|1918-02-1|Not Assessed under the IRIS program.|||||
-Pirimiphos-methyl|29232-93-7|Not Assessed under the IRIS program.|||||
-Polychlorinated biphenyls (PCBs)|1336-36-3|Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas|Linear extrapolation below LED10s|per µg /m<sup>3</sup>|1x10<sup>-4</sup>|Oral, Diet|
-Potassium cyanide|151-50-8|Not Assessed under the IRIS program.|||||
-Potassium silver cyanide|506-61-6|Not Assessed under the IRIS program.|||||
-Prochloraz|67747-09-5|Not Assessed under the IRIS program.|||||
-Prometon|1610-18-0|Not Assessed under the IRIS program.|||||
-Prometryn|7287-19-6|Not Assessed under the IRIS program.|||||
-Pronamide|23950-58-5|Not Assessed under the IRIS program.|||||
-Propachlor|1918-16-7|Not Assessed under the IRIS program.|||||
-Propanil|709-98-8|Not Assessed under the IRIS program.|||||
-Propargite|2312-35-8|Not Assessed under the IRIS program.|||||
-Propargyl alcohol|107-19-7|Not Assessed under the IRIS program.|||||
-Propazine|139-40-2|Not Assessed under the IRIS program.|||||
-Propham|122-42-9|Not Assessed under the IRIS program.|||||
-Propiconazole|60207-90-1|Not Assessed under the IRIS program.|||||
-beta-Propiolactone|57-57-8|Not Assessed under the IRIS program.|||||
-Propionaldehyde|123-38-6|Not Assessed under the IRIS program.|||||
-Propylene glycol|57-55-6|Not Assessed under the IRIS program.|||||
-Propylene glycol monoethyl ether|52125-53-8|Not Assessed under the IRIS program.|||||
-Propylene glycol monomethyl ether (PGME)|107-98-2|Not Assessed under the IRIS program.|||||
-Propylene oxide|75-56-9|Nasal cavity hemangioma or hemangiosarcoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.7x10<sup>-6</sup>|Inhalation|
-Propyleneimine|75-55-8|Not Assessed under the IRIS program.|||||
-Pursuit|81335-77-5|Not Assessed under the IRIS program.|||||
-Pydrin|51630-58-1|Not Assessed under the IRIS program.|||||
-Pyrene|129-00-0|Not Assessed under the IRIS program.|||||
-Pyridine|110-86-1|Not Assessed under the IRIS program.|||||
-Quinalphos|13593-03-8|Not Assessed under the IRIS program.|||||
-Quinoline|91-22-5|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-Quinone|106-51-4|Not Assessed under the IRIS program.|||||
-Radium 226,228|7440-14-4|Not Assessed under the IRIS program.|||||
-Radon 222|14859-67-7|Not Assessed under the IRIS program.|||||
-Refractory ceramic fibers|NA|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-Resmethrin|10453-86-8|Not Assessed under the IRIS program.|||||
-Rotenone|83-79-4|Not Assessed under the IRIS program.|||||
-Savey|78587-05-0|Not Assessed under the IRIS program.|||||
-Selenious acid|7783-00-8|Not Assessed under the IRIS program.|||||
-Selenium and Compounds|7782-49-2|Not Assessed under the IRIS program.|||||
-Selenium sulfide|7446-34-6|Not Assessed under the IRIS program.|||||
-Selenourea|630-10-4|Not Assessed under the IRIS program.|||||
-Sethoxydim|74051-80-2|Not Assessed under the IRIS program.|||||
-Silver|7440-22-4|Not Assessed under the IRIS program.|||||
-Silver cyanide|506-64-9|Not Assessed under the IRIS program.|||||
-Simazine|122-34-9|Not Assessed under the IRIS program.|||||
-Sodium azide|26628-22-8|Not Assessed under the IRIS program.|||||
-Sodium cyanide|143-33-9|Not Assessed under the IRIS program.|||||
-Sodium diethyldithiocarbamate|148-18-5|Not Assessed under the IRIS program.|||||
-Sodium fluoroacetate|62-74-8|Not Assessed under the IRIS program.|||||
-Strontium|7440-24-6|Not Assessed under the IRIS program.|||||
-Strychnine|57-24-9|Not Assessed under the IRIS program.|||||
-Styrene|100-42-5|Not Assessed under the IRIS program.|||||
-Systhane|88671-89-0|Not Assessed under the IRIS program.|||||
-Tebuthiuron|34014-18-1|Not Assessed under the IRIS program.|||||
-Terbacil|5902-51-2|Not Assessed under the IRIS program.|||||
-Terbutryn|886-50-0|Not Assessed under the IRIS program.|||||
-Tetrabromodiphenyl ether|40088-47-9|Not Assessed under the IRIS program.|||||
-,2',4,4'-Tetrabromodiphenyl ether (BDE-47)|5436-43-1|Not Assessed under the IRIS program.|||||
-,2,4,5-Tetrachlorobenzene|95-94-3|Not Assessed under the IRIS program.|||||
-Tetrachlorocyclopentadiene|695-77-2|Not Assessed under the IRIS program.|||||
-,1,1,2-Tetrachloroethane|630-20-6|Hepatocellular adenoma or carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|7.4x10<sup>-6</sup>|Oral, Gavage|
-,1,2,2-Tetrachloroethane|79-34-5|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-Tetrachloroethylene|127-18-4|Not Assessed under the IRIS program.|||||
-,3,4,6-Tetrachlorophenol|58-90-2|Not Assessed under the IRIS program.|||||
-Tetrachlorovinphos|961-11-5|Not Assessed under the IRIS program.|||||
-Tetraethyl lead|78-00-2|Not Assessed under the IRIS program.|||||
-Tetraethyldithiopyrophosphate|3689-24-5|Not Assessed under the IRIS program.|||||
-,1,1,2-Tetrafluoroethane|811-97-2|Not Assessed under the IRIS program.|||||
-Thallium (I), soluble salts|Various|Not Assessed under the IRIS program.|||||
-Thallium acetate|563-68-8|Not Assessed under the IRIS program.|||||
-Thallium carbonate|6533-73-9|Not Assessed under the IRIS program.|||||
-Thallium chloride|7791-12-0|Not Assessed under the IRIS program.|||||
-Thallium nitrate|10102-45-1|Not Assessed under the IRIS program.|||||
-Thallium oxide|1314-32-5|Not Assessed under the IRIS program.|||||
-Thallium selenite|12039-52-0|Not Assessed under the IRIS program.|||||
-Thallium(I) sulfate|7446-18-6|Not Assessed under the IRIS program.|||||
-Thiobencarb|28249-77-6|Not Assessed under the IRIS program.|||||
-Thiophanate-methyl|23564-05-8|Not Assessed under the IRIS program.|||||
-Thiram|137-26-8|Not Assessed under the IRIS program.|||||
-Toluene|108-88-3|Not Assessed under the IRIS program.|||||
-,4-/2,6-Toluene diisocyanate mixture (TDI)|26471-62-5|Not Assessed under the IRIS program.|||||
-Toxaphene|8001-35-2|Hepatocellular carcinomas and neoplastic nodules|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.2x10<sup>-4</sup>|Oral, Diet|
-Tralomethrin|66841-25-6|Not Assessed under the IRIS program.|||||
-Triallate|2303-17-5|Not Assessed under the IRIS program.|||||
-Triasulfuron|82097-50-5|Not Assessed under the IRIS program.|||||
-,2,4-Tribromobenzene|615-54-3|Not Assessed under the IRIS program.|||||
-Tribromochloromethane|594-15-0|Not Assessed under the IRIS program.|||||
-Tribromodiphenyl ether|49690-94-0|Not Assessed under the IRIS program.|||||
-Tributyltin oxide (TBTO)|56-35-9|Not Assessed under the IRIS program.|||||
-,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113)|76-13-1|Not Assessed under the IRIS program.|||||
-Trichloroacetic acid|76-03-9|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-,2,4-Trichlorobenzene|120-82-1|Not Assessed under the IRIS program.|||||
-Trichlorocyclopentadiene|77323-84-3|Not Assessed under the IRIS program.|||||
-,1,2-Trichloroethane|79-00-5|Hepatocellular carcinoma|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|1.6x10<sup>-5</sup>|Oral, Gavage|
-,1,1-Trichloroethane|71-55-6|Information reviewed but value not estimated. Refer to IRIS Summary.|||||
-Trichloroethylene|79-01-6|Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors|Low-dose linear extrapolation from the point of departure (LEC01) with a factor of 4 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk|per µg /m<sup>3</sup>|4.1x10<sup>-6</sup>|Inhalation|
-Trichlorofluoromethane|75-69-4|Not Assessed under the IRIS program.|||||
-,4,5-Trichlorophenol|95-95-4|Not Assessed under the IRIS program.|||||
-,4,6-Trichlorophenol|88-06-2|Leukemia|Linearized multistage procedure, extra risk|per µg /m<sup>3</sup>|3.1x10<sup>-6</sup>|Oral,Diet|
-(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP)|93-72-1|Not Assessed under the IRIS program.|||||
-,4,5-Trichlorophenoxyacetic acid (2,4,5-T)|93-76-5|Not Assessed under the IRIS program.|||||
-,1,2-Trichloropropane|598-77-6|Not Assessed under the IRIS program.|||||
-,2,3-Trichloropropane|96-18-4|Not Assessed under the IRIS program.|||||
-Tricresol|1319-77-3|Not Assessed under the IRIS program.|||||
-Tridiphane|58138-08-2|Not Assessed under the IRIS program.|||||
-Triethylamine|121-44-8|Not Assessed under the IRIS program.|||||
-Triethylene glycol monobutyl ether|143-22-6|Not Assessed under the IRIS program.|||||
-Triethylene glycol monoethyl ether|112-50-5|Not Assessed under the IRIS program.|||||
-Trifluralin|1582-09-8|Not Assessed under the IRIS program.|||||
-,2,4-Trimethylpentane|540-84-1|Not Assessed under the IRIS program.|||||
-,3,5-Trinitrobenzene|99-35-4|Not Assessed under the IRIS program.|||||
-,4,6-Trinitrotoluene (TNT)|118-96-7|Not Assessed under the IRIS program.|||||
-Uranium, natural|7440-61-1|Not Assessed under the IRIS program.|||||
-Uranium, soluble salts|NA|Not Assessed under the IRIS program.|||||
-Urea|57-13-6|Not Assessed under the IRIS program.|||||
-Vanadium pentoxide|1314-62-1|Not Assessed under the IRIS program.|||||
-Vernam|1929-77-7|Not Assessed under the IRIS program.|||||
-Vinclozolin|50471-44-8|Not Assessed under the IRIS program.|||||
-Vinyl acetate|108-05-4|Not Assessed under the IRIS program.|||||
-Vinyl bromide|593-60-2|Not Assessed under the IRIS program.|||||
-Vinyl chloride|75-01-4|Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules|LMS method|per µg /m<sup>3</sup>|4.4x10<sup>-6</sup>|Inhalation|
-Vinyl chloride|75-01-4|Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules|LED 10/ linear method|per µg /m<sup>3</sup>|4.4x10<sup>-6</sup>|Inhalation|
-Vinyl chloride|75-01-4|Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules|LMS method|per µg /m<sup>3</sup>|8.8x10<sup>-6</sup>|Inhalation|
-Vinyl chloride|75-01-4|Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules|LED 10/ linear method|per µg /m<sup>3</sup>|8.8x10<sup>-6</sup>|Inhalation|
-Warfarin|81-81-2|Not Assessed under the IRIS program.|||||
-White phosphorus|7723-14-0|Not Assessed under the IRIS program.|||||
-Xylenes|1330-20-7|Not Assessed under the IRIS program.|||||
-Zinc and Compounds|7440-66-6|Not Assessed under the IRIS program.|||||
-Zinc cyanide|557-21-1|Not Assessed under the IRIS program.|||||
-Zinc phosphide|1314-84-7|Not Assessed under the IRIS program.|||||
-Zineb|12122-67-7|Not Assessed under the IRIS program.|||||
-</t2b>
 ==References==